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ABSTRACT 
CRISPR-Cas9 is a novel gene editing tool that came from the immune system of bacteria 
against viruses, modified to become one of the most efficient technologies in molecular 
medicine. The main goal of this final degree project is to systematically review the state-
of-the-art about the CRISPR-Cas9-based gene-editing tools and their applications in 
cancer therapy and investigation. A total of 142 articles were used, with any type of 
design published from 2010 to 2021 with a 3.0 or higher Journal Impact Factor. In 
investigation, the CRISPR-Cas9-based technology can form knock-outs, knock-ins and 
chromosomal rearrangements mimicking carcinogenesis and, additionally, can be used 
to screen for these modifications with CRISPR-Cas9 libraries. Most of its potential is 
focused towards therapy, with clinical trials on-the-go, being most of the efforts directed 
to correct the inactivation of tumor-suppressor-genes, to delete fusion oncogenes and 
to counteract viral proteins in viral driven cancers. In immunotherapy, it contributes to 
the programming of CAR-T cells and the inhibition of immune checkpoints. Finally, 
CRISPR-Cas9 can screen for mutations responsible for drug resistance, helping to 
establish an alternative to poorly responsive tumors. Even though the risk of off-target 
mutations is the main disadvantage, CRISPR-Cas9 gives hope for high precision 
medicine.  
KEY WORDS: CRISPR-Cas9; Gene editing; mutations; therapy; cancer  
 
RESUMEN  
CRISPR-Cas9 es una nueva herramienta de edición de genes derivada del sistema 
inmune de las bacterias contra los virus, modificada para establecerse como una de las 
más eficientes estrategias disponibles en la medicina molecular. El objetivo principal de 
este trabajo de fin de grado es recordar los mecanismos de reparación del ADN y revisar 
sistemáticamente el funcionamiento del CRISPR-Cas9 y sus aplicaciones en terapia e 
investigación del cáncer. Se usaron 142 artículos publicados desde 2010 hasta 2021 
incluyendo todo tipo de diseño, con un Factor de Impacto superior a 3.0. En 
investigación, CRISPR-Cas9 puede eliminar genes (knock-outs), inserción de genes 
(knock-ins) y reordenar cromosomas en modelos carcinogénicos, aparte de su utilidad 
para rastrear mutaciones con genotecas específicas. En terapia, su uso se ha dirigido al 
desarrollo de ensayos clínicos, encaminados fundamentalmente a restablecer genes 
supresores de tumores, suprimir fusiones oncogénicas o inactivar proteínas tumorales 
virales. En inmunoterapia, ayuda a programar las células CAR-T e inhibir los puntos de 
control. Finalmente, CRISPR-Cas9 puede detectar mutaciones implicadas en la 
resistencia a agentes quimioterápicos, constituyéndose una alternativa en tumores de 
mal pronóstico. Aunque su mayor desventaja sean las mutaciones generadas fuera del 
sitio diana, CRISPR-Cas9 ofrece esperanzas hacia una medicina de alta precisión.  
PALABRAS CLAVE: CRISPR-Cas9; edición genes; mutaciones; terapia; cáncer  
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ABREVIATIONS 
AAV: Adeno-Associated virus 
Acr: anti-CRISPR 
ALK: Anaplastic lymphoma kinase 
APC: adenomatous polyposis coli 
ATR: Ataxia telangiectasia and Rad3-related protein 
BARD: BRCA-associated RING domain 1 
BART: BamHI A rightward transcript 
BRCA1: Breast cancer Susceptibility gene 1 
BRCA2: Breast cancer Susceptibility gene 1 
CAR T cells: chimeric antigen receptor T 
CCDC67: Coiled-Coil Domain-Containing Protein 67  
CGH: Comparative Genomic Hybridization  
CRC: colorectal cancer  
CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats 
crRNA: CRISPR RNA 
CTLA-4: cytotoxic-T-lymphocyte-associated protein 4 
CUL3: Cullin 3  
dCas9: dead Cas9 
DDR: DNA damage response 
dGTP: deoxyguanosine triphosphate 
DGK: diacylglycerol kinase 
DNA-Pk: DNA dependent kinase  
EBNA: EBV nuclear antigen 1 
EBV: Epstein Barr virus  
eGFP: Enhanced Green Fluorescent Protein 
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EGFR: epidermal growth factor receptor  
ELP5: Elongator complex subunit 5 
EML4: Echinoderm microtubule-associated protein-like 4 
ERK: extracellular signal regulated kinase  
EWSR1: EWS RNA Binding Protein 1  
FER: Feline Encephalitis Virus-Related Kinase  
FISH: Fluorescence in situ hybridization 
FL1: Friend leukemia integration 1 transcription factor 
GVHD: graft-versus-host disease  
HPV: human papilloma virus  
KLF11: Kruppel-like factor 11 
KRAS: Kirsten rat sarcoma viral oncogene homolog 
LAG-3: lymphocyte activation gene-3 
LMP1: latent membrane protein 1 
MAN2A1: Mannosidase Alpha Class 2A Member  
MED12: Mediator of RNA polymerase II transcription  
MEK: mitogen-activated protein kinase 
MHC: Major histocompatibility complex 
MLL1: methyltranferase 1  
NCTP: sodium taurocholate co-transporting polypeptide  
NF1: Neurofibromatosis type 1  
NF2: Neurofibromatosis type 2  
NK: natural killer 
NSCLC: non-small cell lung cancer  
P53BER: p53 bound enhancer regions  
PAMs: Protospacer Adjacent Motifs 
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PD-1: Programmed Death 1 
PD-L1: Programmed death ligand 1 
RAMPs: Repeat-associated mysterious proteins  
Rb: retinoblastoma gene/protein 
RNP: ribonucleotide proteins  
Rpn13: 19S proteasome-associated ubiquitin receptor 
S212/S312: Aurora A Kinase to phosphorylate P53  
SCID: combined immunodeficiency disease  
SDF-1: Chemokine stromal cell-derived factor-1 
sgRNA: single guide RNA 
shRNA: short hairspin RNAs 
siRNA: small interfering RNA 
SMAD4: Mothers against decapentaplegic homolog 4 
TADA1: Transcriptional Adaptor 1 
TADA2B Transcriptional Adaptor 2B  
TCEAL1: Transcription Elongation Factor A Like 1 
TCR: T cell receptor 
TGF-β: transforming growth factor β 
TKI: tyrosine kinase inhibitors 
TMEM135: Transmembrane Protein 135 
TRAC: TCRα constant  
tracrRNA: trans-activating RNA 
Treg: T cell regulator 
trRNA: transcription RNA 
VHL: von Hippel Lindau gene 
WNT: wingless-related integration site genes  
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1. INTRODUCTION 
The CRISPR-CAS9 technology can be easily summarized in two words: genetic 
scissors. It is a tool for genome engineering with the ability to precisely cut in a specific 
area of our genes and with that, it is able to edit them. The CRISPR-CAS9-based gene-
editing technology is one of the many tools discovered for this purpose, but its 
popularity and importance is justified by the very simple and effective mechanism that 
relays behind it, and its infinite types of applications in modern medicine have led the 
researchers responsible for its development to be awarded with the Nobel Prize in 
Chemistry in 2020.  
In its origin, the CRISPR-CAS9 is a part of the immune system of bacteria – a rather 
surprising discovery since bacteria are commonly understood as very simple organisms 
characterized by a very primitive cellular system compared to eucaryotic cells.  
Nonetheless, a Spanish researcher, Francis Mojica, from the University of Alicante 
realized back in 1997 that not only bacteria but also archaea have a region in their 
genome composed of several regularly spaced repetitions that nowadays it is termed as 
Clustered Regularly Interspaced Short Palindromic Repeats or CRISPR. Mojica suspected 
that in these organisms with limited complexity, the need to destine a part of their genes 
for these sequences of repetitions had to have a significative importance, especially in 
survival, since the presence in archaea demonstrates an evidence of ancestry (1). 
The role of CRISPR in bacteria is based on incorporating a short sequence of the virus 
DNA that has infected them to their genome with a cluster of short DNA repeats 
separated by ‘spacer’ sequences. This part of the genome containing the virus DNA is 
transcribed as RNA, and therefore is recognized by a trans-activating RNA (tracrRNA) 
that fits perfectly with the spacer sequences. This allows it to be linked by Cas9 proteins, 
that cut this RNA in small pieces that contain parts of the DNA virus. As shown in Figure 
1, once the bacteria is reinfected by an identical virus, it is able to recognize the same 
sequence previously incorporated in their genome, and cleave the virus’s DNA, 
protecting the bacteria from it (2)(3).  
The wide range of possibilities to use this tool in research started a race to publish 
this discovery. And the idea to use this as a gene editing tool was what allowed 
Emmanuelle Charpentier and Jennifer Doudna to step in front of this race and eventually 
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Emmanuelle Charpentier had spent years studying the gene regulation of 
Streptococcus pyogenes whilst Jennifer Doudna work was focused on RNA interference. 
Their paths aligned when they realized that the bacteria’s immune system functioned 
as a RNA interference. Charpentier was the one scientists responsible for finding the 
tracrRNA previously mentioned and needed the help of a biochemist such as Doudna to 
further boost her research on this topic. Once working together, their main goal was to 
make this mechanism as simple as possible – they decided to fuse the tracrRNA and 
CRISPR-RNA in to one molecule that, since then, will come to be known as guide RNA or 
single guide RNA (sgRNA) (4).  
When a cut in our DNA occurs, the human cell has very effective repair mechanisms 
that are triggered, which can generate two different outcomes: in the first place, the 
gene that was cleaved can be inactivated, creating what is known as a knock-out. In 
second place, if a DNA template of a pre-established sequence is inserted in the zone 
that was cut, it can introduce an entire new gene, creating a knock-in (Figure 2).  
A third possibility, also based in using a DNA template, the system can repair the 
gene  that was cut, or edit it, correcting a wrong placed nucleotide (3). Before the 
Figure 2. The CRISPR-Cas9 genetic scissors. This image describes the way the CRISPR-Cas9 technology can be used as a genetic 
scissors (Modified from nobelprize.com). 
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development of the CRISPR-CAS9-based gene-editing tool, the precise control of the 
many steps that are required in this process was a difficult task for biotechnology. 
Therefore, the advantage of this form of DNA editing is the very little complexity needed 
to design a particle that can recognize any sequence we desire and cut it as intended 
with a very high precision: the direct and indirect implications of this discovery are 
unmeasurable to life sciences and medicine. Some of the applications will be described 
below, with a wide range of different approaches in genetic diseases: from monogenic 
illnesses such as sickle cell disease and polygenic and epigenetic pathogenesis, like 
cancer. 
Regarding to monogenic diseases, there are several clinical trials currently underway 
using this technology to cure sickle cell disease (NCT03745287) and β-Thalassemia 
(NCT03655678, NCT03728322) (5–7). Since they are hematological diseases, cells are 
easier to manipulate ex vivo. Excitingly, some preliminary results have been positive, 
since two patients with β-Thalassemia and another one with sickle cell disease no longer 
needed transfusions (8). As a consequence, other monogenic diseases have been 
considered good candidates to be treated with CRISPR-Cas9 technology, such as Leber 
congenital amaurosis 10 (9). Moreover, there is also a clinical study for transplantation 
of CRISPR CCR5 modified CD34+ cells in HIV patients (NCT03164135) (10).  
On the other hand, in cancer, the CRISPR-CAS9-based gene-editing technology has 
the ability to edit human genome to restore tumor suppressor genes (such as TP53) that 
have been inactivated at some stage during carcinogenesis and to disable genes that 
thrive cancer progression. This concept may seem very easy to understand, but the 
technology that was available before CRISPR-CAS9 for this purpose was very time-
consuming, difficult to work with, which translated to a very distant future of applying 
genome editing to everyday medical practice.  
With this new technology it is possible to reproduce in vitro and in vivo models in 
investigation to try to recreate cancer mutagenesis, progression and survival and, 
therefore, providing a new approach to unreveal molecular mechanisms involved in 
carcinogenesis that may serve as new targets for chemo- and immunotherapy. This 
research models are based in three different strategies: generating knock-out genes, 
recreating chromosomal rearrangements and gene correction by introducing knock-ins, 
as a way to try to discover their implications in the cell’s functions and how that ends up 
in developing a tumor that is able to survive infinitely and to grow and spread to affect 
other tissues. They can be also used to recreate a complex environment similar to the 
one behind tumorigenesis by combining different kinds of gene editing: for example, we 
can design CRISPR CAS9 to create loss-of-function of the adenomatous polyposis coli 
(APC) gene (a tumor suppressor gene related to gastrointestinal cancer) or to promote 
proliferation by adding genes such as KRAS that induce cell growth and stimulate mitosis 
(11). 
  Furthermore, because of the similar cellular pathways implied in viral cancers, 
CRISPR CAS9 is able to inactivate oncogenes (E6, E7) that have been induced by viruses 
such as human papillomavirus (HPV), provoking cell apoptosis and suppressing the 
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development of cancer linked to HPV (12). This mechanism might be analogous to many 
other types of virus driven cancers and it is a very promising area of investigation.  
Moreover, the upcoming trend of chimeric antigen receptor T (CAR T) cells for 
immunotherapy was also furthered by the CRISPR CAS9 technology. The strategy is 
based on obtaining a blood sample from a cancer patient in order to reprogram the 
lymphocytes T in vitro to fight against their own tumor and then reintroducing the new 
tumor specific T cells back to the patient. It is in the in vitro manipulation that CRISPR 
CAS9 proves to be useful, since it can be used to generate the T cell antigen receptor 
and to adapt it to recognize specific antigens expressed by the ongoing tumor.  
Last but not least, it has been largely documented that chemotherapy has limited 
effects in inducing remission in several cancers due to the development of drug 
resistance tumors as a consequence of mutagenesis and expression of new resistance 
genes. CRISPR CAS9 can be used to suppress those genes that make the oncogenic cells 
not sensible to former chemotherapy drugs.  
The wide range of applications for CRISPR CAS9 and its attractiveness for lab sciences 
around the world demands an obligation to raise an ethical questioning: which are the 
barriers of this technology? Genome editing is widely discussed since the first studies 
showed up the possibility of editing embryos and even grown humans and this simple 
and effective way of editing genes brings a new concern to the scientific community. 
Besides that, the employment of this mechanism in clinical trials also stands an ethical 
obstacle to overcome. Nevertheless, this tool was able to revolutionize the expectations 
of genetic therapy as it was conceived before and brings very high expectations to its 
future uses in medicine.  
2. OBJECTIVES 
The availability of an easy and specific method for gene editing has always been an 
interesting but unattainable approach for cancer therapy and investigation. However, it 
seems that CRISPR-Cas9 came to revolutionize this field. With this technology, real 
models for tumorigenesis both in vitro and in vivo, can be generated and new targets 
for chemo- and immunotherapy can be found. The main goal of this final degree project 
review is to compile the information about the uses of the CRISPR CAS9 technology in 
cancer, specifically in cancer research and therapy.  
More specifically, the main goals for this project are: to review the state-of-the-art 
of the CRISPR CAS9 applications explaining how it can be used as a gene editor. Next, 
we will remember the cell’s repair systems as a way to better understand the usage of 
this tool and to elucidate how the editing of genes with CRISPR CAS9 is a way to recreate 
tumorigenesis and therefore can be used as an instrument to comprehend better the 
pathogenesis behind cancer. Another objective of this work is to explain the uses of 
CRISPR CAS9 in the field of immunotherapy: the search of new targets, to manipulate 
and correct checkpoint alterations and as a technology that it is useful to facilitate the 
generation of CAR-T cells. Last but not least, we will dedicate a section to describe the 
value of CRISPR CAS9 in viral driven cancers and to portray the usages of this technology 
for chemotherapy resistance.  
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3. METHODS 
This is a systematic review of articles depicting the applications of the CRISPR-Cas9 
technology in cancer research and therapy. The inclusion criteria were articles published 
from 2010 to 2021 consulting PubMed, National Center of Biotechnology Information, 
OMIM and GeneCards databases, written in English, Spanish or Portuguese. No 
restrictions were made in spite of the study design, including experimental and 
observational studies. The papers considered for this project had more than a 3.0 
Journal Impact Factor, using the InCites Journal Citation Reports 
(https://jcr.clarivate.com/JCRLandingPageAction.action). A total of 142 articles were 
selected and therefore will be cited in this final degree project. 
4. HOW OUR CELLS REPAIR THEIR DAMAGED DNA 
To better understand the CRISPR-Cas9 mechanism of action, we will first review the 
cell’s repair mechanisms in order to construct a better comprehension of the subject 
matter.  
The DNA is formed by nucleotides that contain a nitrogenated base, a five-carbon 
sugar (deoxyribose) and a phosphate group. The different types of nucleotides are 
cytidine (C), uridine (U), adenosine (A), guanosine (G) and thymidine (T). When the 
phosphate is removed, the resultant molecule is called a nucleoside. (13) The different 
nucleotides bind to each other in the same strand by phosphodiester unions that are 
covalent bonds, and with other nucleotides in the complementary strand following base 
pairing rules (adenosine to thymine and cytosine to guanosine) with hydrogen bonds.  
The DNA of an eucaryotic cell is damaged daily by thousands of different 
mechanisms that can be grouped in two sets: those generated by the cell itself and the 
other ones as a product of external alterations. The first class is produced by the very 
active cell environment that generates heat and metabolic incidents that can harm the 
DNA. Among these mutations, we can include replication errors, spontaneous base 
deamination, abasic sites, oxidative damage and DNA methylation. The second class can 
be generated by radiations (UV or ionizing), biological agents (bacteria’s toxins and viral 
proteins) or chemical agents: alkylating agents, aromatic amines (such as the polycyclic 
aromatic hydrocarbons found in tobacco) affecting the DNA sequence directly or 
indirectly (14).  
The consequence of these continuous attacks to the cell’s genes throughout the 
evolution has been the development of a very powerful and complex repair system 
whose main goal is to maintain the DNA sequences as unaltered as possible. The 
importance of this repair system is very easily understood if we think of how many 
cancers bear mutations leading to diminished levels of components of the cell’s repair 
structure, such as Breast cancer Susceptibility gene 1 and 2 (BRCA-1 and BRCA-2) related 
to breast and ovarian cancer, Xeroderma Pigmentosum gene associated with skin cancer 
and mutS (E. coli) homolog 2 (MSH2) related to colon cancer.  
The eukaryotic repair mechanisms can be classified in two groups:  those able to 
repair single strand alterations and those able to repair double strand alterations (15). 
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4.1. MECHANISMS OF SINGLE-STRAND BREAK REPAIR 
The design of the double strand DNA is what enables the cell’s repair systems to be 
so effective and precise: when a single strand mutation occurs, the other non-damaged 
strand is available to be used as a template for the reparation, leaving little space for 
errors.  
 Single strand modifications include two different types of local mutations: base 
mutations and nucleotide mutations. Each one has its own repair mechanism described 
below: 
A) Base mutations and base excision repair  
 Base mutations imply the change of one nitrogen base once the DNA is 
replicated, being commonly produced by deamination or depurination that occur 
spontaneously in the cell. This type of modifications to the DNA can be repaired by base 
excision mechanisms.  
 The base excision mechanism consists of a DNA glycosilase that has the 
capability to search in the DNA for alterations using a base-flipping method, that allows 
this enzyme to cover the entire surface of the nucleotides to detect mutations. Once a 
base mutation is encountered, the enzyme removes the selected base from the sugar, 
creating a gap in the DNA (Steps A-C in figure 3). The gap is recognized by an apurinic or 
apyrimidinic endonuclease that cuts the phosphodiester bond. Afterwards, the gap is 
refilled with the correct analogous base, using the other non-harmed strand as template 


















Figure 3. The base excision mechanism. The mechanism of base excision is described in this figure, step by step 
(Adapted from Khan Academy). 
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B) Nucleotide mutations and Nucleotide excision repair 
The nucleotide mutations are more complex and extended when compared to base 
mutations, being usually a product of external cell damage such as tobacco or radiation.  
A common DNA damage is the one produced by UV radiation that creates a bond 
within two adjacent pyrimidines, forming a pyrimidine dimer that makes it impossible 
to replicate the DNA (Step A in Figure 4). The mechanism to repair this kind of mutation 
is similar to the one explained before but using it in a larger scale that includes entire 
nucleotides. The pyrimidine dimer is detected, an excision nuclease eliminates a short 
sequence of nucleotides including the altered ones that is accompanying the mutation, 
the DNA helicase separates the excised nucleotides from the other strand and in the 
following step, the DNA polymerase synthesizes a DNA sequence analogous to the non-
damaged strand (Steps B-C in Figure 4). Finally, the DNA ligase glues the new sequence 
to the preexistent one, repairing the damage (Step D in Figure 4). The step that separates 
the two strands is regulated by Xeroderma pigmentosum (XP) family of ATP- dependent 
helicases, the XPB and XPD. The absence of these proteins produce a diseased named 
like the proteins, where the exposure to UV lighting correlates to a much higher risk of 




Figure 4. The mechanism of repairing the pyramidic dimers formed by UV lights. (Adapted from Khan Academy). 
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4.2. MECHANISMS OF DOUBLE-STRAND BREAK REPAIR 
Double strand alterations include injuries produced by ionizing radiation and 
oxidizing agents that can compromise the double helix structure. However, most 
frequently, they are produced by internal damaging during the formation of replication 
forks that become broken. The difficulty to repair this type of mutations is explained 
because there is no template available to use in comparison to the alterations 
mentioned in the previous section. This explains why these repair instruments are not 
so accurate, and therefore, less efficient when rivalled to the single strand’s one. There 
are two different ways to repair double strand mutations:  
A) Nonhomologous end joining 
When a cut of the DNA affecting the double helix is produced, the nucleotides near 
the break usually are damaged and can’t be repaired, so they are excised of the 
sequence. The exonucleases that are involved in this step are WRN, deficient in Werner 
syndrome; and Artemis, absent int human severe combined immunodeficiency disease 
(SCID). Both of these nucleases are phosphorylated by DNA dependent kinase (DNA-
PK); whose functions are described in the next section. This highlights the importance 
of the correct catalyzation of this stage.  
The remaining nucleotides are linked together by DNA ligase, joining the two ends 
of the strand together. The joining of the two ends is facilitated by DNA-PK, by a process 
involving the formation of a complex that bridges the two ends and help enlist the 
variety of proteins involved in the assembly, such as DNA ligase. The direct consequence 
of the malfunctioning of this cascade of proteins is defective DSB repair, radiation 
sensitivity and increased mutagenesis (17).   
This form of repairing is not a very precise mechanism, nevertheless, humans have 
a very large proportion of DNA that is not constantly activated, so in overall it does not 
produce important alterations to the cell’s functioning. On the other hand, sometimes, 
when the two ends of the strands are connected, they create a fusion of chromosomes 
thus provoking chromosomal aberrations that can difficult appropriate cell division (15). 
B) Homologous recombination 
This way of repairing the double strand breaks (DBS) is only available short after DNA 
replication and before the cell is divided because they use the sister chromatids as 
templates. Just as it was explained before, the advantage of having templates is a more 
accurate reparation and hence, less errors. Moreover, this strategy is not only widely 
used by the cell to restore different kinds of mutations, but it is also the mechanism 
behind the chromosome recombination produced during meiosis that allows to create 
variability among the offspring.  
The basis of the homologous recombination is the existence of several areas in 
human chromosomes that have extensive regions that are very similar to each other, 
what is called homology. And the easiest way to have homologous sequences near to 
each other is after the replication, because the sister chromatids naturally lye together, 
so the non-damaged chromatid can be used as a template for the damaged one.  
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More specifically, after the double strand break is created, nucleases introduce small 
cuts to produce exact 3’ ends. These pieces of DNA with 3’ ends are able to exit the 
damaged DNA and to insert theirselves in between the non-harmed DNA double strand, 
finding the exact homologous region that corresponds perfectly to the nucleotide 
sequence. This process is called strand invasion and it is regulated by Rad51 (18).  
This protein, Rad51, not only has this major role in DNA homologous recombination, 
but also can reinitiate RNA replication forks when damage is detected and promotes cell 
survival when there is genome instability (19).  The importance of understanding its 
function in the cell’s repair mechanisms relies on the fact that mutations in this protein 
can lead to tumorigenesis: when it is overexpressed, it can cause various types of 
mutations that can help proliferation and invasion; on the other hand, its absence has 
also been linked to tumor progression (20). Therefore, its accurate regulation is a crucial 
process in DNA repair.  
Moreover, Bhattacharya et al. (2017) added a new function to Rad51 correlated to 
immunity. They were able to demonstrate that the downregulation of Rad51 triggered 
by itself the activation of the immune system, as a mechanism of marking DNA 
damage. Subsequently, the activated immune system promotes cell apoptosis and the 
exposition of cell’s antigens – a response that favors autoimmunity (19).  
When the homologous pair is created, the DNA polymerase copies the non-damaged 
sequence to introduce the missing nucleotides, repairing the alteration. Once this 
process is completed, the new repaired sequence goes back to the double strand it 
belonged, and the DNA ligase incorporates it to the previously existing chromosome 
(15). 
C) TUMOR SUPRESSOR GENES IMPLICATED IN DOUBLE-STRAND BREAK REPAIR  
 DNA damage response (DDR)  
When the cell is exposed to reactive species of oxygen (ROS) and a genotoxic 
environment, it triggers what is known as a DNA damage response (DDR), that is able to 
screen for DNA damage, correct it, arrest cycle-cell progression and induce apoptosis 
when all of the other strategies fail. The main effectors of this pathway are ATM (ataxia-
telangiectasia mutated), ATR (ATM- and Rad3-Related) and DNA-PKs.  (21). This is 
summarized in Figure 5.  
ATM functions as the DNA damage scan, being regulated by the MRN complex 
(composed of Mre11, Rad50 and Nbs1) that acts as a double-strand break sensor and 
recruits ATM to broken DNA molecules. When MRN detects double strand breaks, it 
enhances its kinase activity in order to activate BRCA-1, Chk2 and p53 phosphorylation. 
The direct consequence of the activation of these proteins is the cell cycle arrest, 
accompanied by promotion of repair and apoptosis.  
Moreover, DSB also activate ATR, which shows overlapping functions with ATM 
when this occurs. The difference, however, is that ATR can be also activated by a variety 
of other DNA damages. For example, in response to a replicative stress there is an 
overexpression of single stranded DNA (ssDNA) that is a consequence of stalled 
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replication. This activates ATR, which triggers a downstream cascade of phosphorylation 
of kinases, “cleans” the replication sites of the ssDNA, initiates cell checkpoints and can 
even induce apoptosis if the damage is beyond repair. The triggering of the cell 
checkpoints rely on the inhibition of CDC25 (22). 
These two pathways also interrelate to each other: first, ATM can promote the 
activation of ATR and vice-versa and they can both bias the recruiting of each other to 
DNA damage. Likewise, they can also phosphorylate each other and can be functionally 










Figure 5. Genes implicated in double-strand break repair. The DNA breaks and stalled DNA replication forks are 
sensed and activate ATM and ATR that function as transducers. Therefore, they induce DNA repair and replication, 
cell-cycle arrest or apoptosis. (Adapted from Maréchal and Lou, 2015) 
 Breast cancer Susceptibility gene 1 and 2 (BRCA-1 and BRCA-2) 
 BRCA1 participates in different aspects of DNA repair. In the first place, it forms 
a heterodimer with BRCA-associated RING domain 1 (BARD) to create an E3 ubiquitin 
ligase activity in order to activate itself when DNA is damaged and participating in DDR. 
In the second place, it is part of the many proteins that set up the cell cycle checkpoints. 
Finally, it directly participates in HR and NHEJ. On the other hand, BRCA2 is responsible 
for recruiting Rad51 to homologous recombination in the repair of double strand breaks 
(16). These  genes are widely known as the breast cancer genes, since they are the main 
genes mutated in hereditary breast cancer, being the life time risk of developing breast 
cancer in BRCA1 mutated women up to 70% compared to non-carriers (23).  
5. CRISPR-Cas9 MECHANISMS  
CRISPR stands for Clustered Regularly-Interspaced Short Palindromic Repeats and 
its structure is made by short repeated sequences of DNA that come up to 28-37 base 
pairs (bp), intercalated by spacers that have the same bp’s length. To better 
comprehend this technology, it is important to recall it is part of the immune system of 
the bacteria. In greater detail, the different parts that composes it are: 
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a) Short Repeated Palindromic Sequences: as shown in Figure 6  when each 
repeated sequence is read in the direction 5’-3’, it is identical to the 
complementary strand, even though they lie in opposite directions (one in 5’-3’ 
and the complementary in 3’-5’). That’s what is called a palindromic repeat. The 
importance of having palindromic sequences is the ability to form loops. The 
repeats are conserved from generation to generation (24). They are represented 





b) Regularly Intercalated Spacers: the palindromic repeats are intercalated 
regularly by what is called spacers. The spacers are a genetic record of all the 
viruses that have infected the bacteria. They can stock a large number of DNA 
sequences, varying from bacterial species (25). 
For example, when a bacteria is attacked by a bacteriophage (a virus that infects 
bacteria), it activates the CRISPR immune system and introduces a part of the 
virus DNA into their own DNA, forming spacers. Therefore, the spacers serve as 
a strategy to have a “criminal record” (or a “genetic record” in this case) of the 
viruses, in order to recognize them again if they are reattacked. The process is 
analogous to the adaptative immune system in humans with memory B cells and 
the high precision is what differentiates it with other immune systems found in 
other bacteria or archaea.  
In contrast with the repeated sequences, since they are a combination of the 
virus DNA, they are not conserved in each generation, changing depending on 
the different virus or plasmid that had invaded the bacteria (24). They 
correspond to the rectangles in Figure 7 
 
Figure 7. Structure of the CRISPR array. (Adapted from Jiang F., Doudna J.A ., 2017) 
The loci also contains a leader sequence that functions as a promoter. It has a length 
of approximately 500bp and has a very significant role in transcription signaling (24). It 
is represented by the black arrow in Figure 7.  
Next to the CRISPR loci there is the Cas gene site that is transcribed as Cas proteins. 
The Cas proteins have a role in every step of the bacteria’s immunity attainment: they 
are needed to incorporate the invading virus DNA in the bacteria, they are involved in 
the production of the transcription RNA (trRNA) and, finally, they also participate in the 
RNA interference phase (26). The steps of the immunity defense will be described in the 
next sections.  
Figure 6. Example of a Palindromic sequence  
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5.1. TYPES OF CRISPR CAS 
First of all, it is necessary to stablish some main concepts that are going to be widely 
used throughout the chapter. When the CRISPR sequence is transcribed, the Cas genes 
are also included, generating a transcription RNA or trRNA, in other words, they are all 
transcribed in one single RNA. When we are only describing the CRISPR part of the 
molecule, it is called CRISPR-RNA or crRNA and it doesn’t include the cas genes. 
The recombination of the CRISPR sequences with the different cas genes generates 
6 different types of CRISPR-CAS, classified accordingly to the Cas protein they use. They 
can be grouped by classes whether they function with a multiprotein cleavage complex 
or a single-protein one (26). The classification is described in the Table 1 below (27). 
 CLASS I CLASS II 
I III IV II V VI 
Cas type Cas3 Cas10 Csf Cas9 Cas9 C2c2 
Effector 
complex 
Multiprotein CRISPR RNA complexes Single multi-domain protein 
Table 1. Classification of CRISPR-Cas systems 
Not all types of systems are found in all bacteria, for example, the CRISPR-Cas9 is 
specially found in Streptococcus pyogenes and Neisseria meningitides (28). The cas1 and 
cas2 are ubiquitous of all bacteria. They play a role in the adaptation part of the immune 
system (29). 
The Type I includes Cas3, a large protein with two distinctive domains: helicase and 
DNAse. In addition, it also has gene encoding proteins that participate in cascade-like 
reactions interplaying with Cas5 and Cas6 families. The participation of all of these 
domains are the way that Cas3 manipulates the crRNA, creating a transcript with long 
spacer repeats (28).  
The type II system is the simplest of all the cas proteins because it has the lower 
number of genes involved. Since it has few genes, the proteins involved have to 
incorporate different domains with distinctive functions in order to work as a whole 
system. Thus, the cas9 protein has at least two nuclease domains that edit the genome 
sequence: a RuvC domain near the amino terminus and the HNH domain in the middle 
of the protein. The HNH has also an endonuclease activity, being the one responsible for 
target cleavage (28). Moreover, it also functions as a cluster sequence that is analogous 
to the ones present in the CRISPR – therefore, it is able to bind to the CRISPR RNA since 
it has a homologous sequence to it and form a complex. This will be better understood 
in the following point. The simplicity of the system made it suitable for using it as a gene 
editing tool. 
Type III has been found in Staphylococcus epidermidis and include Cas10 and Cas6. 
Cas 6 has already been mentioned above, since it also works in the cascade activated by 
Type I. In contrast with the other two types, type III has a large participation of Repeat-
associated mysterious proteins (RAMPs), that possess also RNAse activity, being 
involved in the processing of crRNA. The RAMPs can work in unison with Cas1-Cas2 or 
separately (28).  
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Types IV-VI have been recently described and their course of action is still not well 
understood. All the different types described are represented in Figure 8 
5.2. A BACTERIAL DEFENSE MECHANISM: CRISPR CAS9 
The CRISPR CAS9 defense mechanism is divided in three steps: 1) spacer acquisition 
or Adaptation, 2) CRISPR RNA (crRNA) genesis and 3) RNA interference (27). This is 
represented in Figure 9. 
 
 
Figure 8. Types of CRISPR-Cas9. (Adapted from Wright et al., 2016) 
Figure 9. The three steps of CRISPR immune system: adaptation, crRNA biogenesis and interference. (Adapted 
from Wright et al., 2016) 
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 Spacer Acquisition or Adaptation 
This is the step in which the genetic material of the virus invading the bacteria is 
incorporated in to the CRISPR sequence. The proteins that are responsible for this phase 
are Cas1 and Cas2 that combine to form a heterodimer: Cas1-Cas2 complex.  
When a bacteriophage attacks a bacteria, the viral DNA enters the host cell so it 
can insert itself into the DNA and uses the bacteria’s replication system to replicate. 
When the DNA reaches the cytoplasm, the Cas1-Cas2 complex recognizes short motifs 
that are situated next to the target virus sequence, called Protospacer Adjacent Motifs 
(PAMs). Once Cas1-Cas2 bind to the PAMs, they use their cleavage domain to cut the 
target sequence generating a protospacer DNA. The Cas1-Cas2 complex then acts as an 
integrase, performing two transesterification reactions in the CRISPR array DNA. The 
3’OH of each protospacer strand makes a nucleophilic attack on the repeated sequence 
of the CRISPR array, one at the leader side and one in the spacer side, incorporating into 
it. All of these steps are shown in Figure 10.  Every time the bacteria is invaded by a 












 Biogenesis of CRISPR RNA 
 The CRISPR array is then transcribed to RNA in a tree-step procedure. The steps 
are described in Figure 12. 
1- In the first part, it forms a CRISPR RNA precursor (pre-crRNA), that form loops 
due to the presence of the palindromic repeats, as represented in Figure 11. 
 
 
Figure 10. Formation of the Cas1-Cas2 complex and the generation of the protospacer DNA. (Adapted from 
Wright et al., 2016). 
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Figure 11. The formation of pre-crRNA. (Adapted from Burnistrz et al., 2020). 
2-  In the second step, the tracrRNA is also transcribed and unites itself to the pre-
crRNA, helping the maturation of the structure. It has a hairpin structure, 
represented in green in Figure 12 
 
3- In the third step, the pre-crRNA is then processed by Cas9 (represented by the 
red circle in Figure 10), which with the help of RNAse III (represented by the 
orange triangle in Figure 12) separates the different protospacer regions 
included in the pre-crRNA with the corresponding flanking palindromic repeats. 
Finally, it forms a complex with the Cas9, being called the Cas9-crRNA-tcRNA 
effector complex. As a result, we have one protospacer for each Cas9-crRNA-
tcRNA effector complex (26). In the example represented in Figure 12, the blue 












 RNA interference  
 When the bacteria is reinfected by the same phage, the Cas9-crRNA-tcRNA 
effector complex recognizes the PAMs, which are a short consensus sequence of three 
nucleotides: NGG, represented in Figure 13. Once the recognition is made, the complex 
binds to the virus DNA, allowing the Cas9 proteins to play their role of genetic scissors 
by creating double strand breaks in the target DNA. The ability to create double strand 
breaks is enabled by the two catalytic sites mentioned before: RuvC and HNH, each one 
Figure 12. Assembling of the Cas9-crRNA-tcRNA effector complex. (Adapted from Montecillo et al., 
2020). 
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responsible for breaking a single brand (28). When the breaks are generated, the virus 






Jinek et al., realized that the dual crRNA and tracRNA can be engineered to a single 
RNA to simplify the process. For that purpose, they designed a chimeric RNA that 
contained a recognition sequence at the 5’ end with a hairpin structure that mimicked 
the base-pairing interactions in between crRNA and tracRNA. This sequence is necessary 
for guiding the site-specific cleavage performed by Cas9 (30). This was the initial 
hallmark that opened the gate to the possibility of developing a new technique for 












Figure 14. The design of a single chimeric RNA that functions as the crRNA:tracRNA complex. (Adapted 
from Jinek et al., 2012). 
Figure 13. The protospacer adjacent motifs. Recognition of the PAMs: short consensus sequences of three 
nucleotides – NGG. (Adapted from Mou et al., 2015) 
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5.3. GENE EDITING  
As introduced before, the chimeric unified RNA of crRNA:tracRNA makes the CRISPR 
CAS9 system very simple since it only has 3 components: the CRISPR sequences, cas9 
proteins and a single guide RNA. By designing a CRISPR sequence that is analogous to a 
predeterminate one, the Cas9 is able to recognize it, binding to the target DNA and 
activating the catalyzing domains of Cas9 which generates a double-strand break in the 
DNA. As previously mentioned, double-strand breaks can be repaired in two ways, being 
the Non-Homologous reparation, the most common route followed by the damage 
provoked by CRISPR-Cas9. In spite of the mechanism of repair, the result of the 
activation of the repair systems can be used to create knock-ins, knock-outs, indel 
mutations and frame-shift mutations that can inactivate a whole gene (26). 
Furthermore, since each catalytic site of Cas9 is responsible for breaking one strand, 
CRISPR-Cas9 can be designed to correct or to create point mutations. For that, a cytidine 
deaminase is added to the Cas9 lacking the cleavage domains, called dead Cas9 or 
dCas9. When the dCas9 binds to the target area, the cytidine deaminase changes the 
cytidine to an uracil. Because uracil is not found naturally in the DNA, the cell recognizes 
it promptly, changing it to a thymidine. When DNA replication is initiated, it identifies in 
that strand the newly introduced thymidine, and inserts in the new strand the 
homologous adenosine. Therefore, in a site where initially there was a C-G now it is 
replaced by an A-T (31). 
 In the other hand, not only the catalytic property of Cas9 has an importance in 
gene editing, since it was discovered that when the Cas9 binds to a target DNA without 
being able to cleave it can still inactivate the gene. Therefore, it functions as a 
transcription regulator, silencing genes when the Cas9 binds to them. In order to do 
that, the two catalytic sites, RuvC and HNH, are mutated, but the domain that recognizes 
the target sequence is not manipulated.  Moreover, dCas9 can be united to an RNA 
polymerase, directing it to promotor regions where genes are poorly expressed. This 
new function defines Cas9 as a regulator, not only an inactivator (30). 
 The homology directed repair can produce gene correction, insertion, precise 
point mutations, gain-of-function and loss-of-function mutations. (26).  
 To summarize, the CRISPR-Cas9 gene editing tool permits double-strand breaks 
and single-strand breaks to be done, and also works as a gene promotor regulating 
transcription. This is represented in Figure 15.  
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Figure 15. CRISPR-Cas9 as a gene editing tool: applications. This figure summarizes the functioning of CRISPR-Cas9. 
In the first place, the system cleaves the DNA with the two catalytic sites, HNH and RuvC, producing a DSB. That incites 
an endogenous repair, that can follow two pathways: the NHEJ or the HDR, depending on the presence or not of a 
donor DNA. (Adapted from Jiang F., Doudna J.A., 2017) 
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6. USE OF CRISPR-CAS9 IN CANCER RESEARCH AND INVESTIGATION  
The initial application of the CRISPR-Cas9 technology was its use to recreate the 
molecular changes underlying cancer. Although nowadays tumorigenesis is better 
comprehended, there are still many steps to unreveal and a non-complex gene editing 
tool can boost this grasp forward. This will signify a better way to predict cancer 
behavior, to introduce new targets for treatment or to enhance the ones used until 
today. And, moreover, bringing a more specific approach to cancer treatment that 
directs itself precisely to the tumor cells and, consequently, it might potentially reduce 
the side effects that radio-, chemo- and immunotherapy provokes.  
Three different ways of manipulating the genome can help to understand 
tumorigenesis: generation of knock-out genes, introduction of new genes (knock-in) and 
recreation of chromosomal rearrangements.  
6.1. KNOCK-OUT GENES  
It is known that tumorigenesis doesn’t rely in one single mutation – it is a succession 
of cumulative mutations that collaborate to produce an ideal environment for 
proliferation and growth. With CRISPR-Cas9, this same environment can be mimicked 
by generating a serial sequence of knock-out genes. The best way to illustrate this 
application is compiling the information about very well studied tumors, such as 
colorectal cancer (CRC), where the process of tumorigeneses is well stablished as the 
adenoma-carcinoma sequence, with APC, TP53, KRAS and SMAD4 being the most 
common mutations described until today. For this experiment, two different groups 
were formed: a control group that didn’t have the CRISPR-Cas9 system, and the 
experimental group that introduced this technology inducing different mutations (32). 
Before explaining the experiment, it is important to understand the participation of 
these mutations in CRC:  
a) In a cell expressing the wild version of the APC gene, the β-catenin is 
phosphorylated by APC (which in turn is the final target of a cascade of kinases 
previously activated), inducing ubiquitination and consequently, proteosome 
degradation. The β-catenin is a protein that, when it reaches high concentrations 
in the cell, it is able to migrate to the nucleus acting as a transcription factor to 
induce the activation of the wingless-related integration site genes (WNT), 
involved in cell proliferation. Therefore, the inactivation of β-catenin as a 
consequence of the normal APC’s function leads to suppression of proliferation 
(33)(34). Represented in Figure 16. 
 
b) The KRAS pathway is activated by the epidermal growth factor (EGF) through its 
binding to the EGF receptor (EGFR) located in the cell’s membrane. The 
activation of KRAS induces an enzyme cascade resulting in activation of BRAF, 
mitogen-activated protein kinase (MEK) and extracellular signal regulated kinase 
(ERK), which cooperate stimulating cell growth, proliferation, angiogenesis and 
migration – the 4 elements that sustain a tumor (35). 
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c) SMAD4 also plays a role in tumor suppression, since it inactivates the 
transforming growth factor β (TGF-β) signaling pathway that induces cell growth 
and migration. Consequently, the loss of this gene is correlated with cancer (36). 
 
d) The TP53 gene is known as the cell’s guardian because it has the purpose of 
maintaining the correct functioning of the cell: when the DNA is damaged, p53 
induces repair. And, when the repair is not possible, it stimulates p21 that 
provokes cell cycle arrest by inactivating checkpoint cyclins, thus leading to 
apoptosis (37). 










Figure 17. Transition from Adenoma  to Carcinoma. (Adapted from Nguyen et al., 2018). 
In the work of Drost et al. (2015), they used the CRISPR-Cas9 technology to first 
delete the APC gene, since it is well documented that this process is one of the first steps 
leading to CRC. Once this clonal culture with APC loss is obtained, again with the CRISPR-
Cas9 technology, the TP53 gene was inactivated. As a result, there was a clonal 
expansion of the mutated cells. To generate the KRAS mutation, they designed an 
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oligonucleotide with the oncogenic mutation and two silent mutations that were used 
as a template for homologous recombination. And, finally, the SMAD4 mutation was 
crafted, activating the TGF-β pathway. They observed that, when the 4 mutations were 
engineered in the same cell, the power of this combination is such that environmental 
growth factors are not needed anymore for cell proliferation; subsequently the tumor 
that emerged as a consequence of this mutation sequence is totally independent in 
vitro. The in vivo introduction of these 4 mutations enables the formation of solid 
tumors masses that invade such as actual CRC.  Moreover, only APC and TP53 mutations 
are required for the formation of aneuploidy (32). 
Additionally, the CRISPR-Cas9 technology can be a tool for screening these 
mutations. With that purpose, a lentiviral vector was designed carrying the Cas9 and 
sgRNA simultaneously, added to a short hairspin RNA (shRNA). Afterwards, it was 
introduced to a melanoma model cell line resistant to vemurafenib – a monoclonal 
antibody directed to v-Raf murine sarcoma viral oncogene homolog B, (BRAF) mutations 
and found that the resistance is associated to loss of function of Neurofibromatosis type 
1 (NF1), Mediator of RNA polymerase II transcription (MED12), Neurofibromatosis type 
2 (NF2), Cullin 3 (CUL3), Transcriptional Adaptor 2B (TADA2B) and Transcriptional 
Adaptor 1 (TADA1), discovering new genes involved in CRC that where not characterized 
until this work was published (38). 
 Maresch et al., (2016) designed a mouse model to recreate the multiple knock-
out genes that generate pancreatic ductal adenocarcinoma. For that, they designed an 
intra-pancreatic DNA injection and an in vivo electroporation method that enables the 
insertion of multiple sgRNA, a process impossible with viral vectors. They targeted 13 
tumor suppressor genes involved in pancreatic cancer, testing different variants and 
expression levels, monitoring the mice with MRI imaging. They established that the mice 
that incorporated the sgRNA developed a tumor, in comparison with no tumors in the 
control group after 24 weeks.  They also found that the only targeted gene that wasn’t 
altered was BRCA2, which correlated to the fact that BRCA2 inactivation was needed to 
inhibit KRAS dependent pancreatic ductal adenocarcinoma, but in absence of TP53, it 
was able to induce proliferation. Moreover, they used the CRISPR-Cas9 system to screen 
for metastatic mutations in comparison to other techniques such as Comparative 
Genomic Hybridization (CGH) arrays (39). CGH arrays are a cytogenetic method for 
analyzing variations in the number of copies of chromosomes on a genome wide scale 
without the need for cell cultures. It compares the patient’s genome to a reference one, 
highlighting the differences between them and their exact location (40).  
 Pancreatical ductal adenocarcinoma was also the spotlight of the study by Bakke 
et al. (2019), since it is a cancer that, even though many genetic targets have been 
already been identified, such as KRAS, CDKN2A, TP53 and SMAD4, there is yet a slow 
progress in the development of effective drugs against this type of tumor, which 
ultimately translates into poor prognosis. In this scenario, Bakke’s team performed a 
genetic screen using CRISPR-Cas9 to identify novel therapeutic targets. As a result, they 
were able to find that Proteasome 20S Subunit Alpha 6 (PSMA6) gene was a critical 
component in cancer cell survival and could respond to Bortezomib (41). 
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6.2. RECREATING CHROMOSOMAL REARRANGEMENTS 
The appeal to mimic the chromosomal rearrangements behind tumorigenesis is 
explained by the fact that the suppression of the fusion oncogenes that chromosomal 
rearrangements create seems to be enough to stop cancer growth. In other words, on 
the contrary of what happens with single mutations (that it is necessary to induce 
multiple mutations to recreate the cancer environment and, therefore, it is necessary 
to have multiple targets to stop the cancer from spreading), suppressing one fusion 
oncogene can be enough to treat the tumor. Once the pathogenesis behind each fusion 
oncogene is better understood, new drugs used in immunotherapy can be designed to 
inactivate them (42). 
 The double-strand breaks formed by the CRISPR-Cas9 technology are able to 
recreate inter- and intrachromosomal rearrangements. As an example of an 
intrachromosomal rearrangement that CRISPR-Cas9 was successfully able to induce, we 
can mention the Echinoderm microtubule-associated protein-like 4 (EML4) - Anaplastic 
lymphoma kinase (ALK) - EML4-ALK, found in lung cancer. The fusion oncogene EML4-
ALK is the product of an inversion of 2p, and the reproduction of this phenomenon is 
induced by designing two sgRNA that specifically bind to areas near the EML4-ALK 
mutation, as represented in Figure 18. The advantage of using CRISPR-Cas9 is that the 
fusion that occurs are precise, without the incorporation of excessive nucleotides. This 
is a consequence of the way CRISPR binds to the PAMs, since it doesn’t need further 
end-processing when the cleavage is produced (43).  
 
Figure 18. The intrachromosomal rearrangement that forms EML4-ALK, whose pathogenesis is fundamental in 
lung cancer. (Adapted from Choi and Meyersen, 2014). 
On the other hand, the mutations behind Rhabdomyosarcoma (RMS) consist in 
interchromosomal rearrangements of t(2;13) or t(1;13) leading to the subsequent 
formation of the PAX3/7-FOXO1 fusion gene. This rearrangement can be easily 
recreated by one sgRNA and CRISPR-CAS9 system. The same sgRNA breaks the PAX3 
gene and FOXO1, thus, by non-homologous repair, this two genes are merged (44) 
Figure 19.  
 
Figure 19. The PAX3/7-FOXO1 fusion gene. (Adapted from Choi and Meyersen, 2014). 
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In the studied cited before by Maresch et al., 2018, they also recreated various 
chromosomal rearrangements occurring in pancreatic tumors. More specifically, in this 
cancer it is known that they are 139 intra-chromosomal deletions and 8 inter-
chromosomal translocations per tumor. This study was able to form the following 
translocations and screen for them with aCGH: 
- Involving chromosomes 4 and 18 
o Fusion between Cdkn2b and APC: der(4)t(4;18)  
o Fusion between APC and  Arid1a: der(18)t(4;18)  
- Loss of Chr17 and Chr19 because of der(19)t(17;19) (39). 
Chromosomal rearrangements have been also characterized in prostate cancer and 
hepatocellular carcinoma, generating fusion oncogenes Transmembrane Protein 135 - 
Coiled-Coil Domain-Containing Protein 67 (TMEM135-CCDC67) and Mannosidase Alpha 
Class 2A Member 1- Feline Encephalitis Virus-Related Kinase (MAN2A1-FER). The 
translocation behind these fusion oncogenes are 11q14.2-21 and 5q21 (45) (Figure 20 - 
A). When these oncogenes’ breaking points were tackled with the CRISPR-CAS9 system 
by a pro-drug converting herpes simplex virus type 1 thymidine kinase’ (HSV1-tk), the 
insertion of ganciclovir induced nicks in the previously cited locations, provoking cell 
apoptosis. Ganciclovir is an analogue of 2’-deoxy-guanosine, which activity depends on 
the phosphorylation to ganciclovir monophosphate and consequently in ganciclovir 
diphosphate and triphosphate by the virus kinases in order to inhibit competitively 
deoxyguanosine triphosphate (dGTP) incorporation into DNA and viral polymerases 
(46).  
The strategy performed in this work as follows: they inserted the HSV1-tk with a 
recombinant virus that specifically binds to the breakpoint region of those fusion genes. 
The Cas9 system provokes double-strand breaks that by homologous repair introduce 
the HSV1-tk in the breakpoint gene, being traduced and transcribed with the TMEM135-
CCDC67 gene and forming a HSV1-tk protein. When ganciclovir is internalized in those 
cells, it is phosphorylated by the virus’s kinases into ganciclovir triphosphate, activating 
HSV1-tk that blocks DNA synthesis.  As a consequence, all mouse xenografts studied 
demonstrated a reduced tumor burden (47) (Figure 20C and Figure 21). 
 
Figure 20. Formation 
of TMEM135-CCDC67 
and introduction in 
the cell with action of 
Ganciclovir.  
(Adapted from Chen 
et al., 2017). 
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Figure 21. The HSV-Thymidine kinase Ganglicovir principle. 
All the chromosomal rearrangements and its correspondent studies are gathered in 
Table 2. 
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6.3. KNOCK-IN GENES  
Mutation screenings can be also developed for knock-in genes or gain-of-function 
genes. A remarkable study designed by Korkmaz et al., 2015 used the CRISPR-Cas9 
technology to screen for enhancers that were able to modulate the transcription of p53 
and ERα. ERα is an estrogen activated transcription factor whose overexpression is 
correlated to breast hormone dependent growth and can be treated by using Selective 
estrogen receptor modulators (SERM) modulators. The enhancers related to these 
genes once were the non-coding part of DNA that was once classified as “trash”, and 
nowadays is understood to be vital for cell’s proper functioning and this study further 
supports that idea.  
Korkmatz et al. were able to characterize the regulation of CDKN1A (formerly known 
as p21). If the p53 was inactivated, the cell’s senescence induced by oncogenes was 
diminished, such as well the enhancer regions – they were able to demonstrate that the 
senescence depended on the enhancer, and the enhancer depended on the p53 
expression. Moreover, when the enhancer region was broken, there were also a 
diminished activity of CDKN1A,  further  emphasizing the importance of the enhancer 
for the p53 function (48). 
7. USE OF CRISPR-CAS9 IN CANCER THERAPY AND 
IMMUNOTHERAPY   
7.1. SUPRESSION OF FUSION ONCOGENES 
Above we introduced the importance of being able to suppress fusion oncogenes in 
order to prevent tumorigenesis. Nonetheless, tackling these mutations is not easy, and 
the possibility to use the CRISPR-Cas9 mechanism revolutionized this field. In this line, 
several studies using the CRISPR-Cas9 technology as strategy to attack fusion oncogenes 
to see if, by employing this technique, they were able to eliminate cancer cells. 
Ewing’s sarcoma is one of the most frequent malignant cancers in children, and the 
initial genetic driver behind it is the t(11;22) that forms a fusion oncogene made of the 
EWS RNA Binding Protein 1 (EWSR1) and Friend leukemia integration 1 transcription 
factor (FL1) protein – EWSR1-FL1. To inactivate the fusion oncogene, 4 sgRNA were 
designed to target 2 introns, one in each gene. The cleavage of the introns induced large 
deletions with frameshift mutations. The design made for this is so specific that it only 
actuates in cancer cells, so that healthy cells remain unscathed. The results found that 
the fusion gene inactivation provoked cell’s death, reducing tumor burden and 
mortality. Moreover, when associated with chemotherapy, it created an additive effect 
that potentiates cell death (42). 
7.2. TP53 SUPPRESSION 
As previously mentioned, TP53 is an oncosuppressor gene which absence is part of 
the mutations behind many types of cancer, specially very frequent ones such as lung 
adenocarcinoma, invasive ductal breast cancer, colon adenocarcinoma and high grade 
ovarian cancer (49).  
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There are three different ways in which the TP53 gene can be modified to promote 
proliferation and growth:  
a) Causing single aminoacidic substitutions and leading to inactivation of the 
gene: this is the most common form of mutation of TP53 described until now. It 
is based in single base mutations that induce a frameshift, producing a 
nonfunctioning protein. Normally the mutations occur in a “hot spot” – this 
highlights the fact that it has been selected through time as an advantage for 
tumor growth (50)(8). “Hot spots” are regions in the genome that exhibit 
enhanced rates of recombination in comparison to adjacent regions.  
b) Gain of function of TP53: it upregulates chromatin regulation genes such as 
methyltransferase 1 (MLL1) and MLL2 and even the group of acetyltransferases 
as moz. The consequence of the upregulation of these transferases is histone 
modifications. It has been showed the codependence behind this mechanism – 
TP53 expression is needed for chromatin regulation and vice versa (50).  
c) Epigenetic regulation: until recently, only “permanent” damage to the DNA has 
been reported as responsible for tumorigenesis, nonetheless, epigenetic 
alterations can also have an important role in this process. They consist in 
chemical modifications of DNA and its folding associated proteins that are able 
to regulate, up or down, the expression of a certain gene. They are induced by 
the external cell environment and are less stable when compared to genetic 
variations, meaning they can be reversible. 
As an example of how vital epigenetics can be for human development, in stem 
cells, TP53 is normally inactivated since these are highly proliferating cells. 
Subsequently, when the tissue needs mature cells, the cell’s environment 
induces epigenetic changes to the TP53 gene, stimulating its expression and 
helping the cell mature to a specific cell linage (51).  
When applied to cancer, normally epigenetic alterations like methylation 
provoke TP53 gene inactivation. Because they have the characteristic of being 
reversible, this can be tackled in therapy for inducing tumor suppression. For 
example, Aurora A Kinase phosphorylates P53 (S212/S312) and 
methyltransferases produce changes after transcription that invalidates the P53 
protein function. When these enzymes are targeted, this process can be 
overturned – hence the many drugs using this mechanism that are under study 
(51).  
 
Different strategies have been designed to target TP53. Chira et al., 2018 proposed 
a method that completely deleted the TP53 mutated gene and replaced it entirely with 
a functional copy using the homologous recombination. The system is based on a 
delivery hybrid phage virus induced by doxycycline. Nevertheless, the phage ligand 
proteins that bind to integrins that are overexpressed in cancer can also be highly 
present in other cells such as osteoclasts, which represents a problem since it decreases 
its specificity (52). 
Zhan et al. in 2018, in an elegant experiment, created a genetic sensor that traces 
TP53 reduced expression. First, they identified enhancer regions that were located near 
all TP53 genes, called p53 bound enhancer regions (P53BER). The P53BER were 
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configurated to induce expression of sgRNA and Cas9, producing the CRISPR-Cas9 
system in the cell. Moreover, a plasmid containing the diphtheria toxin was also 
introduced in those cells, being able to kill them. Therefore, when the TP53 was 
expressed, it also expressed the CRISPR-Cas9 system which inactivates the diphtheria 
toxin by cleavage, saving the cell from toxin death. In other words, when the cells had a 
TP53 deficiency, they weren’t able to inactivate the diphtheria toxin and died. This might 
provide a future model for therapeutic and detection of TP53 – by reproducing this 
sensor, cells without TP53 can be killed and prevent proliferation (53).  
Despite the potential applications of these tools, using CRIPSR-Cas9 for editing TP53 
has encountered some difficulties. In the first place, because of the cell’s repair 
mechanisms that are triggered once a double-strand break is generated, when it is tried 
to inactivate TP53 with this type of modification, the cell automatically activates 
apoptosis, loosing edited cells. Furthermore, when TP53 is targeted, is has been shown 
that is not as specific as it would be desirable – it can also tackle genes like VHL or KRAS, 
which obligates of a very thorough examination of the edited cells (8).  
Recently, Enache et al. studied the effects of Cas9 by itself and remarkably, their 
experiments showed that its expression in human cells provokes upstream regulation of 
p53 pathway, with the direct consequence of the expansion of TP53 inactivating 
mutations as a way to surpass the overexpression. The activation of the TP53 has been 
demonstrated to be specific, though it is also enhanced by viral vectors and sgRNA. This 
shed a different light in gene editing with TP53, being more complex than expected and 
can be a potential obstacle for its usage in clinical trials (54).   
7.3. GENERATION OF KNOCK-OUT GENES TO TREAT VIRAL DRIVEN 
CANCERS 
As a contrast from cancers whose origin is not derived from a microorganism 
pathogenesis, viral driven cancer often has one unique oncogenic mutation. This fact 
makes this type of cancer as the most suitable for the use of gene editing therapy such 
as CRISPR Cas9.   
A) HUMAN PAPILLOMA VIRUS (HPV) AND CERVICAL CANCER  
Cervical cancer is a viral driven tumor whose pathogenesis and correlation to the 
human papilloma virus (HPV) is very well comprehended and documented, being 
dependent on the expression of two oncogenes, E6 and E7 (12). These two proteins are 
produced by high-risk HPV Serotypes. E6 binds to the p53 protein, ubiquitinating, and 
therefore, targeting it for proteosome degradation thus inhibiting cell apoptosis and 
promoting senescence. On the other hand, E7 binds to the active retinoblastoma protein 
(pRb), a family of tumor suppressor proteins, and phosphorylates it, producing its 
inhibition and the interruption of the E2F pathway, as shown in Figure 22. Both routes 
are related since the phosphorylation of pRb is also inhibited by p21, a member of the 
TP53 route (55). The absence of homology with human genome makes these two 
proteins a very promising target (56).  
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Different studies used the CRISPR-Cas9 technology in an attempt to inactivate this 
oncoproteins and therefore, to prevent cervical cancer in HPV infected cells. Hu et al., 
designed a plasmid bearing 4 sgRNAs and expressed them in HPV-16 infected cancer 
cells so that they induced double-strand breaks in E7. They concluded that the 
disruption of the E7 gene induced cell apoptosis and restored the tumor suppressor Rb  
(57). In the same line of research, Kennedy et al., also created 4 sgRNAs that inactivated 
E6 and E7 in HPV-16 and HPV-18 cancer cell lines. The protein expression was monitored 
with immunofluorescence and Western Blot methods. The results found were similar to 
the previous study, underlining a positive outcome in the search for a new target, with 
promising conclusions in vitro (58).  
More recently, Zhen et al., took these results as a starting point and went further – 
not only they tested them in vitro, finding accumulation of p53 and p21 and diminished 
proliferation of cancer cells, but also experimented in vivo with cancer mouse models. 
Specifically, they used female mice with an experimental group that had the E6, E7 genes 
with the CRISPR-Cas9 gRNA and a control group without the CRISPR-Cas9. They were 
able to demonstrate weakened tumorigenesis in the CRISPR-Cas9 expressing group  
(56). 
B) HERPES VIRUS FAMILY  
The herpes virus family is a complex group of DNA viruses. They are responsible for 
different types of diseases, variating in range of severity: from simple infections such as 
cold sores to tumors like Hodgkin’s lymphoma. The family can be classified in three 
groups:  
• Alpha Herpesviridae: comprehends the herpes simplex virus 1 and 2, 
responsible for cold sores and genital herpes, respectively. The varicela zoster 
virus belongs to this group too. 
• Beta Herpesviridae: cytomegalovirus, the pathogen behind very common 
congenital effects and chorioretinitis.  
• Gamma Herpesviridae: Epstein Barr virus (EBV), associated with multiple 
malignancies such as nasopharyngeal carcinoma, Hodgkin’s lymphoma, gastric 
cancer, Burkitt’s lymphoma. This is the herpes virus that has been studied the 
most using CRISPR-Cas9 for cancer therapy (59).  
Figure 22. The E7 viral protein inhibits Rb, a oncosuppresor gene. Moreover, E6 blocks apoptosis by 
promoting p53 degradation. The outcome is an outgrowth of desregulated cells. (Adapted from (57) Hoppe 
Seyler et al., 2018). 
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Even though there are antiviral drugs used to treat these infections such as Acyclovir 
and its derivatives that tackle the DNA polymerase, they cannot prevent the latent state 
of the virus since there is not active replication ongoing. The fact that the herpes virus 
can remain latent in B lymphocytes during years is where the danger lies upon the risk 
of developing cancer. This is where the CRISRP-Cas9 technology has delivered a glimmer 
of hope in preventing the oncogenesis (59,60). 
Regarding the EBV, the latent state is generated by the formation of an episome with 
the virus DNA in the infected cell’s nucleus. This process is mediated by the union of EBV 
nuclear antigen 1 (EBNA) to origin of replication zones (60). 
Wang et al. (2014) used a cell line with Burkitt’s lymphoma and targeted them with 
sgRNA to produce deletions of the virus DNA. The direct consequence of this was first, 
the loss of EBV expression, and, therefore, reestablishment of cell apoptosis.  The 
outcome observed didn’t guarantee 100% loss of EBV expression, nonetheless, this 
process can be repeated numerous times and the partial loss could still have a synergic 
effect in the eradication of the virus because it enables the proper functioning of the 
human immune system (60). 
Van Diemen et al., (2016) followed the same approach by designing two sgRNAs that 
targeted the EBNA and areas in the EBV origin of replication in latent infected lymphoma 
cells and used Enhanced Green Fluorescent Protein (eGFP) as a marker of EBV presence. 
They established a reduction of expression of EBV in the latent cells of almost 95%. The 
loss of the expression of the EBV in the human cells prevents their cell cycle promoting 
activity. They were also able to edit the EBV genome using the CRISPR-Cas9 system, by 
targeting miRNA expressed by the virus (59).  
Using a different strategy to arrest EBV expression in latency, Yuen et al. (2015), 
created a recombinant EBV that didn’t express BART (BamHI A rightward transcript) 
suppressed by two sgRNAs. BART’s expression occurs during the latent state of the virus 
hence, its transcription produces cell proliferation and inhibition of apoptosis, being a 
hallmark for malignancy. They did this experiment in epithelial cells (61). Finally, again 
using this technology, they were able to associate the expression of latent membrane 
protein 1 (LMP1) in nasopharyngeal carcinoma so that its inhibition stopped EBV 
proliferation (62). 
C) HEPATITIS B VIRUS (HBV)  
Hepatitis B virus (HBV) is a virus DNA that does its transcription with a reverse 
transcriptase. It its responsible for a large amount of cirrhosis and, subsequently, is a 
very important risk factor for hepatocarcinoma.  
The drugs available for treatment can be divided into two groups: nucleoside 
analogous and INF-α. The first ones tackle the synthesis of DNA and the main issue is 
similar to what happens to EBV: the latent chronic state of HBV is based on a covalently 
closed circular DNA (cccDNA) that survives on human cells and serves as a template to 
produce RNA, without needing HBV proliferation and therefore, DNA replication. In 
other words, the nucleoside analogous have no effect on latent infections and aren’t 
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able to eliminate the HBV from human cells (63). The cccDNA is a viral persistence 
reservoir and its elimination is essential in the cure of HBV (64).  
The HBV replication has 4 open reading frames that produce the Polymerase (P), 
Core proteins (C), Surface proteins (S), and X proteins (X). The different ways to tackle 
this genome can be thought out as strategies for eliminating HBV in hepatic cells. The 
different approaches have been illustrated in Figure 23. 
 
Figure 23. HBV- specific sgRNA targeting regions. (Adapted from Lin et al., 2015). 
Lin et al. (2014) generated eight gRNAs against the genotype A to see if they were 
able to reduce the transcription of Core proteins and Surface proteins: the results found 
were more promising in vitro than in vivo, regardless, both approaches were able to 
induce mutations in HBV (65). Kennedy et al. (2015) directly targeted the reverse 
transcriptase, surface antigen or core proteins and were able to reduce the 
accumulation of cccDNA in infected cells by designing 3 sgRNAs in infected 
hepatocarcinoma cells (66).  
In contrast with the studies showed until now whose main target was the genome, 
Seeger and Sohn (2014) used the HBV receptor, the sodium taurocholate co-
transporting polypeptide (NCTP), as a screening method for permissive line cell cultures. 
Once this cell cultures where determined, they induced double-strand breaks in cccDNA, 
which provoked NHEJ repair mechanisms, inactivating the HBV genome and reducing 
the latent state in the liver (67).  
In addition to the in vitro studies, more recently, Stone et al. (2021), used CRISPR-
cas9 technology in mice chronically infected with hepatitis B virus and were able to 
demonstrate an increased survival in those which HBV genome was edited (68). 
Moreover, in another study, specific gRNAs were designed to tackle conserved regions 
of the HBV genome, diminishing the proportion of cccDNA in mice. In contrast of the 
NHEJ repair mechanism that usually is triggered once the CRISPR-Cas9 system creates 
the double-strand breaks, when multiple sgRNAs are used, the multiple cleavage sites 
make it impossible for this kind of repair. Consequently, the cell is obliged to eliminate 
the DNA templates, and therefore, eradicate the HBV DNA from the infected cells (69) 
Using this technology has encountered different obstacles, though. In first hand, 
some of the impediments are created by the complexity of the infection of HBV: 
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normally, in chronically infected cells there is more than one cccDNA, besides the fact 
that is slowly regenerated by replication (68). On the other hand, regarding the use of 
this technology, the ideal vector still has to be found: it was hypothesized that the most 
appropriated was an adenovirus vector, but more recent studies implied that the 
nucleoside analogous could inhibit their transduction (70). Moreover, the possibility of 
off-target mutations still concerns researchers and has to be token in consideration.  
7.4. CELLULAR ENGINEERING FOR CAR-T CELLS 
Chimeric antigen receptor T (CAR-T) cells are beginning to revolutionize 
immunotherapy, especially in hematologic tumors such as acute lymphoblastic leukemia 
and multiple myeloma. In order to understand how it is possible to apply CRISPR-Cas9 
to ameliorate this technology, it is needed to comprehend the structure and functioning 
of the CAR-T cells: The approach consists of autologous T cells that are engineered in 
vitro and then re-introduced with their new receptors to act against the tumor in vivo 
(71).  
More specifically, as shown in Figure 24, the first step in this process is designing 
the CAR which consists of fragments of the T cell receptor (TCR) bounded to antibody, 
therefore, the structure is a member of the family of the immunoglobulins. It has an 
extracellular target-binding protein, a hinge region, a transmembrane protein that 
anchors the CAR to the membrane and intracellular signals (72). The critical phase in this 
step is creating the antigen specificity, since this is the basis for the success of the 
therapy. And, since it is able to directly bind to the antigen, it is not Major 
histocompatibility complex (MHC) restricted. Next, DNA that encodes to form the CAR 
is introduced with retroviruses in the T cells. The T cells are cultivated and therefore, 
selected. Finally, the functioning population of T cells can be infused back to the patient 
(Figure 24) (73).  
Figure 24. CAR-T cell functioning. The T cells are recognized and isolated, being manipulated in vitro. Then, they 
are selected and expanded, so they can be re-infunded to the patient. The result is special T cells that can better 
recognize the tumor and attack it. (Adapted from Kulemzin et al., 2017) 
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Besides the basic structure of the CAR, many more features can be added to 
enhance tumor specific cytotoxicity, to mitigate secondary effects, to increase potency, 
and to overcome tumor immunosuppression. For example, by the inhibition of 
interleukin genes that mediate cytotoxicity, introduction of chemokine receptors to aid 
the attachment of the T cell to different sites, and the addition of suicide genes that 
stablish a security system (72).  
In this matter, Jung et al. (2018) knocked out with CRISPR-Cas9 the diacylglycerol 
kinase (DGK) in order to increase the CD3 signaling in human primary T cells. The DGK is 
an enzyme that functionally inactivates the diacylglycerol acid, which is responsible for 
interacting with TCR signaling, therefore, its inhibition has great potential in 
immunosuppression therapy. They also found that manipulated cells were resistant to 
suppressor factor such as TGF-β and prostaglandin E in vitro. In addition, this technology 
was also rehearsed in mouse xenographic models with glioblastoma and an enhanced 
TCR signaling was found (74). 
In addition, the tumor micro-environment consists mainly in the production of 
inhibitory interleukins, such as TGF-β, guaranteeing the immunosuppression and 
therefore, persistence and proliferation. It has a direct effect in the cytotoxic function 
of CD8+ cells and favors CD4+ Treg conversion. Tang et al. (2020) used CRISPR-Cas9 to 
knock-out the TGF-β receptor II (TGFBR2) in CAR-T cells in a double in vitro - in vivo 
xenograft model; one being derived by cell lines and the other, in patient derived cells. 
The results found underly an heightened efficiency of the CAR-T cells even when the 
tumor was reinoculated (75).  
On the other hand, cancer patients not always are the best donors: as a 
consequence of the disease there can be insufficient number of T cells or they can be 
non-functioning cells. This highlights the need to be able of creating allogenic universal 
T cells with minimal graft-versus-host disease (GVHD) or the rejection of the T cells (71), 
GVHD consisting in an immune response initiated by the recognition of white blood cells 
from the donors organ by the host’s lymphocytes. And the advantage relies not only in 
the fact that it can be obtained by healthy donors, but that tumor specificity is not 
needed: they are based on an antibody molecule that recognizes tumor antigens and 
performs a switch that can bind to the CAR. To improve the generation of universal CAR 
-T cells, initially many different editing tools were used, and more recently, CRISPR-Cas9 
was incorporated to help this process (76).  
To avoid the GVHD, it is needed to knockout the TCRα constant (TRAC) and the TCRβ 
constant, which can be easily accomplished with the CRISPR – Cas 9 and also 
demonstrated that it can increase T cell potency. In addition, the internalization and re-
expression of CAR -T cells as a consequence of multiple exposure of the antigen is more 
effective, reducing the exhaustion of the activity of these cells (77).  
Furthermore, the issue of rejection can also be tackled by eliminating the heavy 
chains of HLA-1 expressed in human cells, also called β2 microglobulin. And because of 
the high efficiency of the CRISPR-Cas9 activity, this can be easily done. Besides, to 
further enhance the reduction of immunogenicity, the TRAC can be also knocked out. 
Likewise, blocking the PD-1 signaling, which consists of an immunosuppression strategy 
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developed by tumors, can further ameliorate the design (78). This same idea was 
improved by using a one-shot CRISPR protocol that could simultaneously knock-out the 
TRAC, β2 microglobulin and PD-1, speeding the process of engineering the CAR-T cells. 
This same study also knocked out the Fas receptor (CD45) that has a major role in T cell 
apoptosis, binding to the Fas-ligand and inducing cell death that downregulates the 
number of CAR -T cells (79). Figure 25.  
On the other side, the absence of HLA-1 makes the CAR -T cells susceptible for 
natural killer (NK) cells recognition and cytotoxicity. To prevent this from happening, a 
HLA-E can be express in the cell membrane, functioning as a minimal polymorphic HLA 
that is sufficient to prevent NK cell activation (80).  
Besides the GVHD, the activity of CAR -T cells in the organism can produce cytokine 
release syndrome, a complication that has a severity range of manifestations, and could 
be life-threatening. It is a consequence of the binding of the CAR to the antigen, 
producing the activation of nearby cells such as endothelial cells, producing a massive 
release of cytokines  (81). This side effect can be mitigated by knocking out the 
granulocyte macrophage colony-stimulating factor (GM-CSF) with CRISPR-Cas9 in these 











Figure 25.  Strategies to better enhance CAR T cells. They can be divided in three different strategies. The first one is 
the development of allogenic T cells, to save the usage of cancer patients’ cells. The main problem is the graft versus 
host disease that can be prevented by manipulating the TCR. The second strategy is the broadening of the CAR target. 
Finally, the last strategy is to enhance efficiency, by continuous antigen encounter and immunosuppressive 
environment factors. (Adapted from Jung and Lee, 2018). 
CD7 is a transmembrane glycoprotein physiologically expressed in T cells and NK 
cells with a role in the co-stimulation derived from the union of the TCR with the antigen, 
but it is also pathologically expressed in lymphoblastic T-cell leukemia and T-cell 
lymphomas. Therefore, the CD7 was idealized as a target for immunotherapy against 
those tumors, which failed as a consequence of the attack on T cells. A way to correct 
this issue is to design CAR-T cells that have the CD7 gene knocked out with CRISPR-Cas 
9, where they were able to expand without compromising the TCR recognition (83).  
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As promising as this fields is, it also has obstacles regarding its application in a larger 
scale envisioning clinical trials, such as a large-scale protocol to maximize reproducibility 
and, therefore, easier techniques are needed. In that matter, besides using the 
conventional methods for the transduction of CRISPR, like lentiviruses or adenoviruses, 
a simpler model was developed. It is based on delivering the CRISPR-Cas9 in the form of 
ribonucleotide proteins (RNP) with electroporation (84,85). And, as previously 
introduced, the off-target mutations always remain a concern with this technique.  
 The first in-human trial employing CRISPR-Cas9 technology is being developed, 
using multiplexing with sgRNA to enhance the efficacy of engineered T cells in cancer, 
which is explained further below (86).  
7.5.  IMMUNE CHECKPOINTS  
A) PD-1 AND PD-L1  
The immune checkpoints have a major role in developing an adequate immune 
response against cancer cells. They consist of proteins in the T cell’s membrane that are 
able to recognize different ligands in tumor cells, and, therefore, to activate or to 
inactivate the T cell. The most explored immune checkpoint nowadays is the 
Programmed Death 1 (PD-1) and Programmed death ligand 1 (PD-L1). The cancer cells 
express the PD-L1 that binds to the PD-1 in the T cell, initiating an inactivating response 
and consequently, escaping from the immune system.  
Inhibiting the PD-1 – PD-L1 union is a common target for immunotherapy and many 
tumors use drugs targeting these proteins as a standard treatment. The most well-
known cancer in this matter is the non-small cell lung cancer (NSCLC), which can be 
treated with pembrolizumab, a monoclonal antibody against PD-1. Another way to 
tackle this union could be by editing out the PD-1 which has been done after series of 
experiments, culminating in the design of a human clinical trial.  
In the first place, Su et al. (2016) demonstrated that ablating the PD-1 with CRISPR-
Cas9 using electroporation methods was feasible in vitro (87). Furthermore, Rupp et al. 
(2017) used a similar design, but using a lentivirus form of transduction and also found 
positive results, being also reproduced in vivo in a xenograft model (88). Additionally, 
this technology has begun to be directly used against cancer cells, for example, in 
glioblastoma cells (89,90). Likewise, It was also demonstrated to have positive effects 
when applicated in mouse xenograft models with multiple myeloma (91), hepatocellular 
cancer (92) and melanoma (93). 
Finally, human clinical trials are starting to be developed. Lu et al. (2020) 
(NCT02793856), knocked-out the PD-1 ex vivo and then reintroduced the cells in late-
stage NSCLC patients, a process similar to the CAR -T cells previously mentioned. They 
chose patients that hadn’t had an effective response after many lines of treatment, to 
compensate the risks of off-target mutations. And, moreover, to enhance the safety of 
the therapy, they performed whole-genome and next-generation sequencing to 
monitor those mutations. The results support the safety and feasibility of gene editing 
therapy, with side effects like leukopenia, lymphopenia, fatigue, fever, arthralgia and 
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skin rash that were well tolerated, and just one case of grade 1 arrhythmia which cause 
remains unknown was reported.  Regarding the concern for off-target mutations, they 
detected a low rate, being most of them located in introns that didn’t produce important 










In addition, Staudtmauer et al. (2020) used the CRISPR-Cas multiplex gene editing to 
suppress the expression of TCR and PD-1 so as to create a cancer-specific TCR in four 
patients with advanced cancer. The multiplex editing produced chromosomal 
translocations, nonetheless, there wasn’t important consequences in the patients 
derived from these mutations (95).  
The cycline dependent kinase 5 (Cdk5) serin develops a substantial role in the PD-1 
pathway by inducing the production of Interferon-γ (IFN-γ) which induces upregulation 
of the expression of PD-L1 in cancer cells. As a consequence, the tumor is able to evade 
the immune system  (96). Ardelt et al. (2018) inhibited Cdk5 in hepatocellular carcinoma 
cells with CRISPR-Cas9 both in vitro and in vivo, enhancing the efectiveness of Sorafenib 
and preventing resistance (97). 
B) CTLA-4 
In a similar perspective previously commented for PD-1 and PD-L1, cytotoxic-T-
lymphocyte-associated protein 4 (CTLA-4) also has a pivotal role in immune checkpoints. 
It is expressed in activated T cells and in regulatory T cells (Treg), and the consequence 
of binding to B7 (in competition with CD28, which binding leads to a co-stimulatory 
signal) is an inhibitory signal, preventing the production of IL-2, a proinflammatory 
interleukin. Therefore, CTLA-4 also represents a very effective mechanism of evasion of 
the immune response that can be triggered by cancer cells, subsequently, is also a very 
good candidate to be considered as a major target in therapy. In fact, there is an 
antibody designed against this protein, called ipilimumab, which its use has been 
approved for metastatic melanoma (98).  
Figure 26. Patients with NSCLC have 
their T cells removed and the PD-1 
edited out. Therefore, they are not 
able to activate PD-L1 and induce an 
immunosuppressor response from T 
cells. (Adapted from Lu et al., 2020) 
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Because of the restrictions of the usage of ipilimumab, a different approach to tackle 
this target was needed. Hence, as an extension of the CAR-T technology, CTLA-4 can be 
knocked out with the CRISPR-Cas9, enhancing the anti-tumor activity. This was 
demonstrated by Shi et al. (2017) in vitro and in a xenograft mouse model in vivo, which 
results determined  a 40% reduced tumor viability, that could be explained by increased 
apoptosis and major activity of caspases (91). This same method was replicated in 
different studies such as the one performed by Peixoto et al. (2016) (99). 
C) LAG-3 
Inhibiting the two classical immune checkpoints previously described, PD-L1 and 
CTLA-4, was an important hallmark in immunotherapy, nonetheless, resistance started 
to emerge very importantly. The way to overcome this issue was to tackle other immune 
checkpoint previously not confronted – starting a race to better describe these 
interactions and to develop drugs that could regulate them. In this context, the 
lymphocyte activation gene-3 (LAG-3) was qualified as promising immune checkpoint to 
be considered. 
Its function is to stablish a co-inhibitory signal that suppresses T cell activation, with 
a synergic activity to PD-1. In CD4+ cells that are invading a tumor, they are able to 
inhibit the downstream cascade of activation, leading to an early exhaustion of the 
attack on cancer cells. As predicted, the double inhibition of PD-1 and LAG-3 can reverse 
the exhaustion and increases T cell formation (100).  
The first drug against LAG-3 was developed in 2006, nowadays there are several 
treatments under drug trials. Moreover, the combined action of these drugs with 
nivolumab (an PD-1 inhibitor) showed promising results in melanoma resistant cancer 
(101). Zhang et al. (2018) used CRISPR-Cas9 to knock-out the LAG-3 in CAR-T cells in cell 
culture and in a xenograft mouse model, with an efficient approach and a similar 
functioning to conventional CAR-T cells (102). 
8. DRUG RESISTANCE 
The main obstacle that cancer treatment has to overcome nowadays is drug 
resistance. Most of the documented drug resistance is acquired and consists of positive 
selection of the mutated resistant clones, a process analogous to antimicrobial 
resistance. Until today, the strategy used to diminish resistance is to combine different 
drugs, however, this can make the results less predictable. Hence, developing new drugs 
that have different targets can be very expensive and time-consuming, what emphasizes 
the need of characterizing and understanding the mutations that underly within and to 
defeat them (103). Because CRISPR-Cas9 can be used to knock-out the genes that allow 
the cancer cells to escape from responding to drugs and to screen for these mutations, 
it is becoming a major strategy in order to guarantee cancer remission.  
8.1. USING CRISRP-CAS9 IN RESEARCH: identification of potential targets  
CRISPR-Cas9 is a simple way to develop a large-scale screening program to 
investigate gene function, since the specificity of the system depends of short guide 
sequences, therefore, the employment of oligonucleotide libraries allow to scan a large 
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pools of genes (104). This can be directly applied to search for potential new targets that 
can be behind therapy resistance and, consequently, be modified genetically or 
inhibited by new designed drugs. In this section, all the different applications of this 
screening method will be explored.  
As an example of this application, Wang et al. (2014) designed a loss-of-function 
genetic screen with a genome-scale  lentiviral sgRNA library containing 73,000 sgRNAs 
to generate knockout collections in two cell lines:  
a) Screening for 6-thioguanine (nucleotide analog) resistance: most of the screens 
showed loss-of-function DNA mismatch-repair genes such as MSH2, MSH6, 
MLH1 and PMS2 with a low frequency of off-targets  
b) Screening for Etoposide (DNA topoisomerase II inhibitor) resistance: the obvious 
result was that the loss-of-function of topoisomerase II enabled resistance to 
Etoposide (since it is its main target). Nonetheless, besides the expected result, 
they also found that CDK6 is involved in the function of Etoposide, and, 
therefore, its loss determines resistance. (105) 
A similar approach to the use of CRISPR-Cas9 as a genetic screen was developed by 
Kasap et al. (2014), being it called DrugTargetSeqR. They also screened for two different 
drugs:  
a) Ispinesib (inhibits a mitotic motor protein called kinesin spindle protein (KSP), 
impeding mitosis thus leading to cell cycle arrest): they stablished that 
acquisition of resistance has no correlation to the DNA mismatch repair genes, 
in contrast to the results found in resistance for nucleotide analog 6-thioguanine. 
In a more specific procedure, they demonstrated that mutations of Kinesine-5 
were behind the resistance, being either point mutations (such as A133P and 
D130) or deletions. 
b) YM155 (cytotoxic drug): they weren’t able to find any specific mutations 
correlated to YM155 resistance, leading to the conclusion that the lack of 
response is due to diminished cell proliferation (106). 
Furthermore, Xu et al. (2019) used a genome-wide CRISPR loss-of-function screen to 
detect the mutations behind the loss of efficiency of gemcitabine in either locally 
advanced or metastasic gallbladder cancer. As a result, the loss of Elongator complex 
subunit 5 (ELP5) was identified as a primordial mechanism behind gemcitabine 
resistance, resulting in an inhibition of apoptosis mediated by p53 because of 
diminished translation of p53 mRNA. Therefore, they were able to demonstrate that the 
expression of ELP5 allows to predict the sensitivity to gemcitabine and elucidates it as a 
possible target for molecular therapy or gene editing (104).  
Additionally, the poor response behind osteosarcoma’s therapy also incited Wang 
et al. (2021) to design a genome-wide screen to better identify the molecular 
mechanisms behind cancer stem cells that compose this tumor. They concluded that 
Kruppel-like factor 11 (KLF11) acted as a tumor suppressor in those cancer stem cells, 
and its activation has a synergic effect in chemotherapy. Subsequently and since there 
are not well stablished markers for chemotherapy success in this tumor yet, the 
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monitorization of KFL11 can be useful. Their study demonstrated that the CRISPR-Cas9 
technology can be efficiently applied for screening cancer stem cells, which until this 
work was not well explored (107). 
High grade serous ovarian cancer is an aggressive tumor with small chances of 
survival (five-year survival is <50%), in which more than 80% of the overall cases develop 
chemotherapy resistance, being the treatments mainly based on platinum or 
taxanes. The process behind this resistance has been studied before and some targets 
have been identified: mutations in BRCA1/2, overexpression of ATP-binding cassette 
sub-family B member 1 (ABCB1), also known as Glycoprotein 1 (P-gp) or multidrug 
resistance protein (MDR-1) and the large family of anti-apoptotic proteins such as B-Cell 
lymphoma (BCL). Nonetheless, even though these mutations were identified, the direct 
correlation and pathogenesis behind resistance remained unclear, which motivated 
Stover et al. (2019) to create a pooled near-genome-scale open reading frame 
overexpression screen and a pooled genome-scale CRISPR-Cas9 knock-out screen for 
resistance to cisplatin and paclitaxel. The BCL-2 family were the most clearly proteins 
associated to resistance, in concrete BCL-XL and MCL1. Therefore, combining drugs 
against this family of proteins with conventional chemotherapy can be a more 
efficacious approach to treat this cancer. However, this can be limited by cross-
resistance or enhanced expression of other anti-apoptotic proteins (108). 
ATR inhibitors are a new approach to cancer therapy, being Berzosertibe the most 
advanced group representative, a monoclonal antibody being evaluated in a phase I 
clinical trial showing promising results and safety (109).  
Ruiz et al. (2016) developed a wide screen CRISPR-Cas9 to determine the resistance 
behind the ATR inhibition and their findings proved it was correlated to the deficiency 
of CDC25 and mutant Cnot8.  As CDC25 is considered as an oncogene and it is overly 
expressed in various tumors, its augmented levels make the cancer cells more 
susceptible to this drug and could be used in combination with chemotherapy for 
ameliorating survival and remission.  Moreover, they were able to reestablish the 
sensitivity to ATR inhibitors by using Wee1 inhibitors, a protein that inhibits Cdk1, 
involved in cyclin-dependent passage of the cell’s checkpoints, opening the field for 
combined drugs with ATR inhibitors and Wee1 inhibitors (110).  
Docetaxel and cabazitaxel combined with androgen deprivation therapy is the 
standard treatment for prostate cancer and specially in castration-resistance prostate 
cancer. In the last group, the survival results are moderated and seem to be a 
consequence of taxane resistance (111). Rushworth et al. (2020) conducted an in vivo 
dropout docetaxel sensitation CRISPR screen in prostate cancer that identified 17 genes, 
being Transcription Elongation Factor A Like 1 (TCEAL1) the most expressed in all the cell 
lines (112).  
All of the resistance mutations cited above are summarized in Table 3. 
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Table 3. Drug and resistance mutations 
DRUG MO RESISTANCE MUTATIONS 
NUCLEOTIDE ANALOG 6-THIOGUAINE 
DNA mismatch repair genes: 
MSH2, MSH6, MLH1 and PMS2 




Kinesin spindle protein 
inhibitor 
Kinesine-5 
YM155 Cytotoxic agent No correlation 




Disruption of microtubules 
BLC-2 family 
BERZOSERTIBE ATR inhibitor CDC25 and Wee1 
DOCETAXEL Disruption of microtubules TCEAL1 
VEMURAFENIB BRAF inhibitor 
NF1, NF2, MED12, CUL3, TADA2B,  
and TADA1 
8.2. APPLICATIONS IN THERAPY  
In this section the uses of CRISPR-Cas9 to tackle mutations that produce resistance 
to different cancer therapies will be discussed, being divided in molecular targeted 
agents, chemotherapy agents and finally, multi-drug resistance.  
A) MOLECULAR TARGETED AGENTS 
The emergence of tyrosine kinase inhibitors (TKI) in lung cancer has revolutionized 
the therapeutical approach offered to patients – besides surgery, radiotherapy and 
conventional chemotherapy, more direct molecular therapy could be used to improve 
cancer survival. For lung cancer, the main target is EGFR, which activation induces cell 
proliferation, neo-angiogenesis, invasion and metastasis and it is inhibited by erlotinib 
and gefitinib as a first line of treatment.  Nevertheless, within 2 years, most patients 
develop resistance to erlotinib, which eventually was demonstrated to depend on a 
mutation in position 790 of EGFR, substituting threonine with methionine (T790M). 
Other common mutations are the deletion of exon 19 and a point mutation in exon 21 
that substitutes leucine with arginine at codon 858 (L858R). This provoked the 
generation of second line and third-line drugs that could bind to that mutation 
selectively.  
Hopelessly, though predictably, resistance has already appeared against the last 
lines of treatment, which highlights the need to use a different strategy – correct the 
resistance mutation itself. Tang and Shrager (2016) described this method as “molecular 
surgery” in which a knock-out of every resistance mutation was created with CRISPR-
Cas9 technology   (113).  
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Figure 18. Mutations that confer resistance to TKI. T790M is the mutation responsible for resistante to erlotinib. 
These mutations can be identified in patients with lung cancer, and they can be replaced or destroyed in order to 
enhance the sensitivity to TKIs. (Adapted from Tang and Shrager, 2016). 
Proteasome inhibitors such as bortezomib are a well-stablished line of treatment for 
multiple myeloma, nonetheless, again resistance is a main problem mitigating the 
effectiveness of this therapy. The resistance could be overcome by inhibiting 19S 
proteasome-associated ubiquitin receptor (Rpn13), a protein involved in the recognition 
of ubiquitylated proteins and also associated to immune response signaling. This can be 
achieved by knocking it out with CRISPR-Cas9, and it was demonstrated to have positive 
results in vitro and in vivo in multiple myeloma mouse models, defeating proteosome 
inhibitor resistance (114).  
Mantle cell lymphoma is a non-Hodgkin lymphoma that also responds to bortezomib 
in advanced stages. Chen et al. (2016) elucidated a new mechanism of resistance to this 
drug, correlated to the Chemokine stromal cell-derived factor-1 (SDF-1) and its receptor 
CXCR4, expressed in the bone marrow: the resistant cancer cells in a rich environment 
of ROS upregulate the expression of CXCR4, which stimulates the stem-cell properties 
that these cancer cells have. Moreover, they also upregulate autophagy for survival in 
Bortezomib treatment. Therefore, when CXCR4 was inhibited, the sensitivity to 
Bortezomib was increased (115). 
B) CHEMOTHERAPY INTERCALATION AGENTS 
Tang et al. (2019) targeted mutated TP53 in osteosarcoma cancer cells with CRISPR-
Cas9 and were able to find heightened response to doxorrubicin (116). Moreover, the 
same result could be achieved when PD-L1 is knocked out with CRISPR-Cas9 (117).  
C) MULTI-DRUG RESISTANCE  
Multidrug resistance could be a consequence of overexpression of MRD1, an ATP-
dependent efflux pump which encodes for P-glycoprotein, a membrane protein that 
works as a drug transporter. As a consequence, it produces resistance to taxanes, 
anthracyclines and vinca alkaloids (118). Since its identification, many strategies have 
been used to minimize its effects:  
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a) Developing MDR1 inhibitors that could be introduced as adjuvants together with 
chemotherapy: there are three generations of these drugs with a wide range of 
response; the first and second failed due to increased toxicity and the third still 
has unpredictable results in clinical trials (119). 
b) Using different pathways for delivering drugs, such as nonviral small interfering 
RNA (siRNA) and inorganic nanocarriers (120,121).  
c) Down-regulation of MDR1: the first strategy to achieve this was the use of 
siRNAs, with the downside of needing constant downregulation to properly 
function. Recently, CRISPR-Cas9 offers an alternative, as explored by Ha et al. 
(2016) and Liu et al. (2016). 
Ha et al. (2016) knocked out MDR-1 gene with CRISPR-Cas9 and exposed those cells 
to doxorubicin, resulting in an enhanced response. However, this could not be  
potentiated with further injections of CRISPR-CAS9 plasmids, since the MDR-1 is not the 
only resistance mechanism (118). Liu et al. (2016)  applied the same strategy for 
osteosarcoma: first, they established the relationship between poor survival in this 
cancer to MDR-1 expression and doxorubicin resistance with a meta-analysis; next, they 
knocked out this gene with CRISPR-Cas9, restoring its sensitivity to doxorubicin (122). 
Furthermore, the suppression of CD44 with CRIPSR-cas9 in drug resistant osteosarcoma 
cell lines culminated in the downregulation of MDR-1 and subsequently, ameliorated 
chemotherapy response (123).  
Additionally, not only MDR-1 overexpression leads to multidrug resistance, since the 
mutation of numerous resistant determinant genes also have the same result. For 
instance, when KLF1 is knocked out, it offers resistance to Etoposide and to 
Gemcitabine. Moreover, when topoisomerase IIA is absent, not only it results in 
decreased sensitivity to the main target, etoposide, but also to doxorubicin (124). 
Likewise, knocking out Urokinase plasminogen activator (uPA) receptor (uPAR) with 
CRISPR-Cas9 in cancer cells resistant to 5-fluoruracile, cisplatin, docetaxel and 
doxorubicin showed lessened multidrug resistance (125). 
9. HUMAN CLINICAL TRIALS WITH CRISPR-Cas9 TECHNOLOGY 
The wide applications of CRISPR-Cas9 in cancer culminated by the increased 
development of human clinical trials. The first study (NCT02867345) was used in 
prostate cancer, in a dose-escalation study of ex-vivo knocked-out, expanded and 
selected PD-1 knock-out autologous T cells to achieve the maximal tolerant dose (126). 
Moreover, another dose-escalation study with PD-1 knock-out T cells was used for 
metastatic renal cell carcinoma (NCT02867332) (127). 
For EBV associated malignancies, the safety of PD-1 knockout EBV- CTL cells is being 
evaluated in another clinical trial (NCT03044743). It is based on collecting peripheral 
blood lymphocytes and the PD-1 gene will be knocked out with CRISPR-Cas9 technology, 
being then reintroduced in the respective patient. The patients will be submitted to 4 
cycles of therapy (128).  
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Another phase 1 safety and efficacy study is being developed on allogenic CRISPR-
Cas9 engineered T cells (CTX110) in subjects with relapsed or refractory B-cell 
malignancies, including Non-Hodgkin lymphoma and B-cell lymphomas  (NCT04035434) 
(129). Finally, a phase 1 trial of autologous T cells engineered to express NY ESO-1 TCR 
and CRISPR-Cas9 gene edited to eliminate endogenous TCR and PD-1 for multiple 
myeloma (NCT03399448) (86).  
Table 4  summarizes all the human clinical trials developed in cancer using the 
CRISPR-Cas9 editing method. 
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10.MARKETING GENE EDITING KITS WITH CRISPR-Cas9 
The diversity of applications of CRISPR-Cas9 and, consequently, the high demand of 
the use of this technology worldwide opened a market of selling CRISPR kits. They 
consist in a variety of different vectors, including plasmids (non-viral vectors), lentivirus, 
Adeno-Associated virus (AAV) and nanoblades (described by the company itself as “tiny 
CRISPR ninjas for genome editing difficult cells”-Addgene); synthetic guide RNAs and 
Cas9 nucleases, customized CRISPR gRNA libraries and mammalian cell line services. 
Moreover, they fulfill the need for intermediate reagents such as longer DNA 
oligonucleotides of final reagents of RNA, for example. To summarize, it’s a ready-to-
use commercial strategy.  
All of these tools can be personalized depending on the research it is destined for, 
with different approaches:  
a) Genome engineering: including cutting, base editing and performing nicks. 
b) Transcriptional regulation: activating, interfering and epigenetics. 
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c) RNA targeting: RNA targeting, editing and empty gRNA vectors. 
d) Purify: to isolate a given genomic locus. 
e) Tag: to tag a gene of interest. 
f) Visualize: using fluorescence methods.  
Some of the most popular companies that have developed CRISPR-CAS9 commercial 
kits are GenScript, ThermoFisher Scientific, Addgene, PNA Bio, gBlocks, Sigma and 
Synthego (130–132).  
11.DISCUSSION: CHALLENGES FOR THE FUTURE AND EXPECTATIONS  
CRISPR-Cas9 has revolutionized the way we can edit genes. Some years ago, it was 
an almost impossible task restricted to large laboratories. Nowadays, the technique has 
been reduced to a simple kit that can be bought off the internet (literally). The main 
appeal is simplicity and low cost, which can make it accessible and attainable in a large 
scale. Besides, it can be easily directed to a specific locus and has a high rate of specificity 
compared to previously used gene editing methods.  
For cancer, the applications are almost endless, and they can be grouped accordingly 
to two main objectives: to better elucidate the mechanisms behind tumorigenesis and 
therefore, have a better grasp of how cancer works molecularly and to restore those 
mutations behind this process for therapy.  
The ability to easily produce knock-ins, knock-outs and chromosomal 
rearrangements makes it the perfect tool to recreate the tumor’s environment, 
highlighting the function of well-known genes and discovering the paper of new ones. 
Likewise, this can be a strategy to find new targets for immunotherapy and to 
understand the mutations that underly behind drug resistance. Correlating to the last 
one mentioned, CRISPR-Cas9 can screen for mutations in chemotherapy resisting cell 
lines and thus, sheds a light into mutations that can be edited or inhibited to maximize 
tumor regression and survival.  
In therapy, CRISPR-Cas9 can be used to knock-out fusion oncogenes that produce 
common cancers such as Ewing’s sarcoma, or can restore the function of TP53, one of 
the most common tumor suppressor genes inactivated in tumorigenesis. Another very 
pivotal role of CRISPR-Cas9 is found in viral driven cancers, since the specific inhibition 
of the virus’s proteins can even cure and prevent cancer growth, as was demonstrated 
for cervical cancer and HPV, Burkitt’s lymphoma and VEB, hepatocarcinoma and VHB. 
One of the highlights and very promising areas for CRISPR-Cas9 is using it to design CAR-
T cells, in which the technology is useful in almost every step of the CAR-T generation 
process: it can be used to create the TCR, to modulate the microenvironment that 
surrounds the T cells and to prevent GVHD, rejection and cytokine release syndrome 
after the infusion. In the same line of immunotherapy, the immune checkpoints stablish 
themselves as a very attractive area for CRISPR-Cas9 gene editing, since it can be used 
to ablate PD-1 directly without the need of monoclonal antibodies, being this the main 
subject of an ongoing clinical trial with encouraging results. Similar strategies can be 
thought out for CTLA4 and LAG-3.  
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The aim of this technology is to stablish a personalized medicine, based on the 
specific mutations found in the tumor that can be tackled with all the weapons that we 
desire: chemotherapy, monoclonal antibodies, molecular targeted agents, 
immunotherapy and gene editing. It is a high precision oncological medicine that gives 
high hopes in having better results of progression-free survival and average survival.   
The most debated disadvantage of CRISPR-Cas9 and the headlines of discussion 
of many articles in prestigious scientific journals are the off-targets effects of CRISPR-
Cas9 gene editing. The controversy started with a paper by Schaefer et al. (2017), now 
retracted, that exposed the unexpected mutations after CRISPR-Cas9 editing, consisting 
in a single nucleotide mutation that provoked blindness of the mouse models used in 
their research (133). In addition, larger scale mutations have also been reported, like in 
the article by Kosicki et al. (2018) that described large deletions and complex 
rearrangements in the repair of double-strand breaks induced by CRISPR-Cas9 (134). 
Rayner et al. (2019) described large-scale deletions and disruptions of targeted locus 
that was only detectable by using standard Sanger sequencing and locus-specific  
fluorescence in situ hybridization (FISH) (135). Moreover, the need to screen for these 
errors has been neglected in the beginning of the usage of this technology. Scientific 
disputes aside, off-target mutations, in bigger or smaller scale are still an obstacle in 
using CRISPR-Cas9 further on than mouse models.  
The immediate and obvious consequence of the off-target mutations are non-
desirable or non-predictable alterations like the described by Schaefer et al. But, in 
addition, when CRISPR-Cas9 is used to characterize tumorigenesis and to locate new 
targets for immunotherapy, off-target mutations can suppose misinterpreted results: 
for instance, there can be a mutation that can be thought out to be pivotal for cancer 
proliferation, but it was a consequence of the CRISPR gene editing and not produced by 
the tumor itself.  
Many strategies have already been implemented to avoid these inaccuracies in 
the methodology: using two guide sequences for Cas9 to increase specificity, better 
designed sgRNAs and screening methods (135). For example, for some locus, CRISPR-
Cas9 has low efficiency and has difficult access, therefore, Xi et al. (2015) developed a 
two-step “pop-in/pop-out” system that allowed them to tag that specific loci, so it can 
be easily detected by western blots and determined the localization by fluorescence 
microscopy, avoiding its binding to another location (136). Another important hallmark 
in reducing off-target mutations is the discovery of anti-CRISPR (Acr) proteins, which 
originally were found in Type I CRISPR-Cas systems, nowadays consisting of over 50 Acr 
that interact with a variety of cas: Cas3, Cas9, Cas12… As the name suggests, they block 
the activity of CRISPR-Cas9, using different targets to do so: they can block the 
interaction or recognition to the PAM site, preventing the binding to the DNA (137,138). 
They impede the assembly of the crRNA (139) and they also bind to the HNH 
endonuclease domain to inhibit DNA cleavage (138).They function as a “temporal, 
spatial or conditional control of CRISPR activity” (140), which can also reduce 
cytotoxicity of the editing tool in target tissues (141). 
The final goal in CRISPR-Cas9 technology is being able to use it widely and with 
security in humans, being the clinical trials the major screening they have to overcome. 
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The first challenge that can be encountered in human clinical trials is the immugenicity 
of Cas9 in the host;  the Cas9 protein is recognized by the human immune system as an 
antigen, and it triggers specific T-cells response, besides the innate immune response 
and humoral immunity (142). Another obstacle is guaranteeing a proper induction of 
the CRISPR-Cas9 into the host cells, which sometimes can be difficult in certain tissues, 
requiring non-viral vectors. There are many non-viral methods being used in in vitro 
stages, such as electroporation of nanoparticles, but they do not present the same 
results when translated to human trials. Many other strategies are being developed such 
as phage-derived nanoparticles, plasmid encapsulated lipopolymers and liposome-
templated hydrogel nanoparticles (103). 
As any other editing tool that has emerged in the scientific history, ethical 
concerns always reemerge, especially when considering editing embryos and therefore, 
inducing mutations that can be passed through generations, and also to avoid ecological 
impairment and genetic enhancement. Nevertheless, until now, most of the efforts have 
been directed to somatic cells and monogenic or polygenic diseases, which can 
postpone this discussion further along.  
12.CONCLUSION  
CRISPR-Cas9 is a novel gene editing tool characterized by its easiness, efficiency and 
for being an affordable system. It is based on an ancient immune system that bacteria 
uses to avoid the infection from viruses, which was modified to achieve its simplest form 
for programming it to edit human DNA, a discovery that rendered Jennifer Doudna and 
Emanuelle Charpentier the Chemistry Nobel Prize in 2020. One of the most thought-out 
applications for its use is in cancer, since it can be effortlessly utilized to manipulate the 
DNA and recreate tumorigenesis, working towards a better understanding of it and, 
therefore, elucidating new targets for therapy. Likewise, it can directly correct mutated 
genes that are responsible for carcinogenic events or stablish new mutations that could 
revert them. The vast variety of applications culminate in assaying them in human 
clinical trials, which consists in the last final step in expanding its use and stablishing it 
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